8-k - sec€™s telephone number, including area code 011-353-1-268-2000 not applicable former name...

0001193125-15-190908.txt : 201505180001193125-15-190908.hdr.sgml : 2015051820150518072907ACCESSION NUMBER:0001193125-15-190908CONFORMED SUBMISSION TYPE:8-KPUBLIC DOCUMENT COUNT:39CONFORMED PERIOD OF REPORT:20150518ITEM INFORMATION:Other EventsITEM INFORMATION:Financial Statements and ExhibitsFILED AS OF DATE:20150518DATE AS OF CHANGE:20150518

FILER:

COMPANY DATA:COMPANY CONFORMED NAME:Endo International plcCENTRAL INDEX KEY:0001593034STANDARD INDUSTRIAL CLASSIFICATION:PHARMACEUTICAL PREPARATIONS [2834]IRS NUMBER:000000000STATE OF INCORPORATION:L2FISCAL YEAR END:1231

FILING VALUES:FORM TYPE:8-KSEC ACT:1934 ActSEC FILE NUMBER:001-36326FILM NUMBER:15871831

BUSINESS ADDRESS:STREET 1:MINERVA HOUSE, SIMMONSCOURT ROADSTREET 2:BALLSBRIDGECITY:DUBLIN 4STATE:L2ZIP:00000BUSINESS PHONE:353-1-268-2000

MAIL ADDRESS:STREET 1:MINERVA HOUSE, SIMMONSCOURT ROADSTREET 2:BALLSBRIDGECITY:DUBLIN 4STATE:L2ZIP:00000

FORMER COMPANY:FORMER CONFORMED NAME:Endo International LtdDATE OF NAME CHANGE:20131203

FORMER COMPANY:FORMER CONFORMED NAME:Sportwell LtdDATE OF NAME CHANGE:20131126

8-K1d928010d8k.htm8-K

8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuantto Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): May18, 2015

ENDO INTERNATIONAL PLC

(Exact name of registrant as specified in its charter)

Ireland001-36326Not Applicable

(State or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(I.R.S Employer

Identification No.)

FirstFloor,MinervaHouse,SimmonscourtRoad,Ballsbridge,Dublin4,IrelandNot Applicable

(Address of principal executive offices)(Zip Code)

Registrants telephone number, including area code 011-353-1-268-2000

Not Applicable

Formername or former address, if changed since last report

Check the appropriate box belowif the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item8.01Other Events

On May18, 2015, Endo International plc, a public limited companyincorporated under the laws of Ireland (the Company), issued a joint press release with Par Pharmaceutical Holdings, Inc., a Delaware corporation (Par), announcing that the Company entered into an Agreement andPlan of Merger (the Merger Agreement) with Par, Endo Limited, a public limited company incorporated under the laws of Ireland, Endo Health Solutions Inc., a Delaware Corporation, Banyuls Limited, a private limited companyincorporated under the laws of Ireland (Buyer), Hawk Acquisition ULC, a Bermudian unlimited liability company (Merger Sub) and Shareholder Representative Services LLC, a Colorado limited liability company,solely as the Stakeholder Representative (as defined in the Merger Agreement), pursuant to which Merger Sub will merge with and into Par (the Merger), with Par surviving the Merger as a wholly owned subsidiary of Buyer. A copy ofthe joint press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. In addition, the Company provided supplemental information regarding the Merger in connection with a presentation to investors. A copy of thepresentation is attached hereto as Exhibit 99.2 and is incorporated by reference herein.

Item9.01Financial Statements and Exhibits.

(d)Exhibits

Exhibit

Number

Description

99.1Joint Press Release, dated May 18, 2015, of Endo International plc and Par Pharmaceutical Holdings, Inc.

99.2Investor Presentation of Endo International plc, dated May 18, 2015.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersignedhereunto duly authorized.

ENDO INTERNATIONAL PLC

Date: May18, 2015

By:

/s/ Matthew J. Maletta

Name:

Matthew J. Maletta

Title:

Executive Vice President,

Chief LegalOfficer

EXHIBIT INDEX

Exhibit

Number

Description

99.1Joint Press Release, dated May 18, 2015, of Endo International plc and Par Pharmaceutical Holdings, Inc.

99.2Investor Presentation of Endo International plc, dated May 18, 2015.

EX-99.12d928010dex991.htmEX-99.1

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

Endo to Acquire Par Pharmaceutical, Strategically Expanding Generics Business to

a Top 5 Industry Leader

- Transaction valued at $8.05 billion is transformative for Endo, creating a powerful platform for

future growth and further strategic M&A

- Creates specialty pharmaceutical company with one of industrys fastest growing generics businesses

and expanded product portfolio, pipeline, technology platform and manufacturing capabilities

- Positions Endo for long-term double-digit organic growth, strong cash flow and financial flexibility

- Accretive to non-GAAP diluted earnings per share within first 12 months with double-digit accretion

to non-GAAP diluted earnings per share expected in 2016

- Projected total operationaland tax synergies of $175 million while strategically maintaining R&D

- Par CEO Paul Campanelli to join Endo to lead generics business

and join Executive Leadership Team

- Closing anticipated in 2H 2015

DUBLIN and WOODCLIFF LAKE, NJ, MAY 18, 2015 -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) and Par Pharmaceutical Holdings, Inc. today announcedthat they have entered into a definitive agreement under which Endo will acquire privately-held Par from TPG in a transaction valued at $8.05 billion, including assumption of Par debt. The combination will create a leading specialty pharmaceuticalcompany with a generics business that is one of the industrys fastest growing and among the top five as measured by U.S. sales. It is also expected to help drive long-term double-digit revenue growth for Endo. The transaction has beenunanimously approved by the Boards of Directors of Endo and Par, and is supported by the management teams of both companies. There are no further shareholder approvals required. The purchase price will consist of approximately 18million shares($1.55 billion of value based on the 10-day volume weighted average share price of Endo ending on May15, 2015) of Endo equity and $6.50 billion cash consideration to Par shareholders. Endo has secured fully committed financing from DeutscheBank and Barclays to fund the cash consideration. Endo expects to implement a permanent capital structure to finance the transaction prior to the close that would include a combination of cash, debt and an equity offering.

Our generics business, Qualitest, continues to be an extremely attractive and effective growth driver forEndo. This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products while also transforming Endo, creating a powerful corporate platform for future growth andstrategic M&A, said Rajiv De Silva, President and CEO of Endo. We believe the acquisition of Par underscores the continued execution of Endos value-driven M&A strategy and helps deliver on our goal of achieving double-digitrevenue growth for the overall business over the long-term. We are also excited to welcome Paul Campanelli to the Endo leadership team. With more than 25 years of experience in the generics industry and nearly 15 years at Par, Paul has demonstrateda clear track record of success in innovation and strategic management in specialty generics.

This is an exciting time of growth andopportunity in the generics and specialty pharmaceutical arenas. Par Pharmaceutical is committed to significantly expanding our scope, capacity and capabilities to realize the maximum value of our rich and diversified product portfolio and R&Dpipeline. We believe our combination with Endo best positions us to do so, said Mr.Campanelli, CEO of Par Pharmaceutical. We share Endos goal of developing and commercializing generic drugs in areas of greatest revenuepotential, complex formulations and longer life cycles. I look forward to joining the Endo team and working together to achieve that goal.

ParPharmaceutical is a privately-held company that was acquired through a take-private transaction by an affiliate of TPG in 2012.

Over the last threeyears, we have enjoyed partnering with the Par team to create a more diversified company with expanded capabilities, an enhanced product pipeline and more robust business development opportunities, all resulting in significant growth, saidTodd Sisitsky, managing partner of TPG Capital North America. The success of Par, in part, reflects our continued focus and operational expertise in the growing healthcare industry. It has been a

pleasure to invest in such a great company and support Pars outstanding management team as they have grown and diversified their business. As part of Endo, Par will be well-positioned todrive future growth and we look forward to continuing to participate in the companys next chapter of success.

Strategic Benefits StronglyPosition Endo for Future Growth and Value Creation

Acquisition Reshapes Generic Pharmaceuticals Landscape While Transforming Endos Platform for Future Growth

With the addition of Pars product portfolio and R&D pipeline, Endos already rapidly growing generics business unit is expectedto become one of the largest and fastest growing in the industry, with double-digit revenue growth over the long-term and a broad product pipeline. The Par portfolio includes nearly 100 products in multiple dosage forms and delivery systems,including oral solids, oral suspensions, injectables and high barrier-to-entry products. This portfolio is highly profitable with increasing adjusted gross margins. The transaction is also expected to help drive double-digit growth for Endosoverall business, expanding the companys corporate scope, size and future M&A potential.

R&D Pipeline Provides Attractive Long-Term Opportunity

Par offers a solidpipeline consisting of more than 200 Abbreviated New Drug Applications (ANDAs), 115 of which were filed with the U.S. Food and Drug Administration (FDA) as of December31, 2014. Approximately 33 percent of the filed ANDAs are potentialfirst-to-file or first-to-market opportunities and 75 percent of the overall development portfolio consists of Paragraph IV and first-to-file programs all of which could provide a period of market exclusivity if approved. It is expected thatthe Par R&D pipeline could generate approximately 20 to 25 ANDA filings each year in 2015, 2016 and 2017.

Significant Operational& Tax Synergies

Given the complementary nature of thecompanies generics portfolios and operations, Endo estimates the transaction will generate $175 million in operational and tax synergies that are expected to be realized within the first 12 months following the completion of the transaction,while strategically preserving investment in the R&D pipeline to help drive long-term organic growth.

Strong Financial Profile Drives Shareholder Value

Following thetransactions completion, Endo expects to have an even stronger financial profile with enhanced cash flow and improved financial flexibility to continue to execute on its corporate strategy. The transaction is expected to be accretive toadjusted diluted earnings per share (EPS) within the first 12 months after transaction close and result in double-digit accretion to adjusted diluted EPS in full year 2016. For 2016, Endo anticipates that EBITDA generated by Par will translate intoa transaction multiple of approximately 10 to 11 times pro forma adjusted EBITDA on a post-synergized basis.

Continued Execution and Development of Leadership Team Position Endo to Achieve Corporate Goals

Endo continues to deliver on its corporate strategy to build a leading global specialty pharmaceutical company and, ultimately, improving liveswhile creating value. This acquisition moves the company forward in its focus on maximizing the value of each of its core businesses, participating in business areas that offer significant growth and favorable margins and transforming its operatingmodel to maximize growth potential and cash flow generation. It also adds to the leadership team at Endo, bringing the proven experience and expertise of Mr.Campanelli to lead and grow the companys generics business.

Robust Cash Flow Generation and Prudent Financing Structure Provides for Rapid De-Levering

Endo anticipates that the transactions expected financing structure will consist of approximately 18million Endo shares ($1.55billion in value based on the 10-day volume weighted average share price of Endo ending on May15, 2015) and $6.50 billion in cash consideration to Par shareholders. Endo has secured fully committed financing from Deutsche Bank and Barclays andintends to fund the cash consideration through a combination of cash, debt and an equity offering. This financing combination provides the ability for Endo to rapidly de-lever back to the three to four times net debt to EBITDA range in the 12 to 18months following the close of the transaction. The structure also allows for future financial flexibility and continued execution of Endos M&A strategy.

The transaction is expected to close in the second half of 2015 and is subject to regulatory approval in the U.S.and certain other jurisdictions, as well as other customary closing conditions.

Advisors

Barclays, Deutsche Bank, and Houlihan Lokey acted as financial advisors to Endo. JP Morgan acted as financial advisor to Par and its shareholders. Skadden,Arps, Slate, Meagher& Flom, LLP were Endos legal advisors and Ropes& Gray, LLP acted as legal advisors to Par and its shareholders.

Conference Call and Webcast

Endo and Par executives willhost a conference call at 8:30 AM ET to discuss todays announcement. The conference call can be accessed by dialing (866)497-0462 (U.S. dial-in) or (678)509-7598 (international dial-in) and the passcode is 50504381. A replay of thecall will be available from May18, 2015 at 12:30 PM ET until 11:59 PM ET on June1, 2015 by dialing (855)859-2056 (U.S./Canada) or (404)537-3406 (international) and by entering the passcode 50504381. Accompanying slides willbe available on Endos website. Endo will webcast the call to all interested parties through its website: www.endo.com.

About Endo International plc

EndoInternational plc is a global specialty pharmaceutical company focused on improving patients lives while creating shareholder value. Endo develops, manufactures, markets and distributes quality branded pharmaceutical and generic pharmaceuticalproducts as well as over-the-counter medications though its operating companies. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more atwww.endo.com.

About Par Pharmaceutical Holdings, Inc.

Par is a specialty pharmaceutical company that develops, manufactures and markets safe, innovative and cost-effective pharmaceuticals that help improve patientquality of life. Par Pharmaceutical offers a line of high-barrier-to-entry generic drugs, while Par Specialty Pharmaceuticals provides niche, innovative brands. Par Sterile Products develops, manufactures and markets both branded and generic asepticinjectable pharmaceuticals. For press release and other company information, visit www.parpharm.com.

About TPG

TPG is a leading global private investment firm founded in 1992 with over $67 billion of assets under management and offices in San Francisco, Fort Worth,Austin, Dallas, Houston, New York, Beijing, Hong Kong, London, Luxembourg, Melbourne, Moscow, Mumbai, So Paulo, Shanghai, Singapore and Tokyo. TPG has extensive experience with global public and private investments executed through leveragedbuyouts, recapitalizations, spinouts, growth investments, joint ventures and restructurings. The firm has a strong history of healthcare investing and its well-known investments include Aptalis, EnvisionRX, Fenwal, Healthscope, IASIS Healthcare,Immucor, IMS Health, Quintiles Transnational and Surgical Care Affiliates, among others. For more information visit www.tpg.com.

This press release does not constitute an offer to sell securities.

Forward Looking Statements

This press release containsforward-looking statements relating to the acquisition ofParbyEndo. All statements other than historical facts included in this press release, including, but not limited to, the statements byMr. De Silva,Mr.Campanelli and Mr.Sisitsky, and other statements regarding the timing and the closing of the transaction, the expected benefits of the transaction, the expected accretion to earnings resulting from the transaction, expected productapprovals, Endos plans to operate Par and any assumptions underlying any of the foregoing, are forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate orunknown, or unknown risks or uncertainties

materialize, actual results could vary materially fromEndosexpectations and projections. Risks and uncertainties include, among other things, uncertainties as to the timing ofthe acquisition; the possibility that various closing conditions to the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the transaction; thattheFDAor other regulatory authorities do not approve any product(s) in the manner desired by Endo on a timely basis, or at all; that there is a material adverse change to Par; that the integration of Pars businessintoEndois not as successful as expected; the failure ofEndoto achieve the expected financial and commercial results from the transaction; other business effects, including effects of industry, economic or politicalconditions outside Endos control; transaction costs; the outcome of litigation, actual or contingent liabilities; as well as other cautionary statements contained elsewhere herein and in Endos periodic reports filed withtheSECand Canadian securities regulators, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K. Giventhese uncertainties, you should not place undue reliance on these forward-lookingstatements, which apply only as of the date of this press release.Endoexpressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Additional information aboutEndoisavailable at www.endo.comor you can contact the Endo Investor Relations Department by calling 484-216-0000. Additional information about Par is available at www.parpharm.com.

Regulation G Reconciliation

This press releasereferences EBITDA, Non-GAAP diluted earnings per share and adjusted gross margin, which are financial measures that are not prepared in conformity with accounting principles generally accepted inthe United States(GAAP). We refer to suchmeasures as non-GAAP financial measures. We define EBITDA as net income before interest, taxes, depreciation and amortization. We define Non-GAAP diluted earnings per share as earnings per share attributable toEndoas calculated underGAAP, as adjusted to remove the effects of (1)certain upfront and milestone payments to partners; (2)acquisition-related and integration items, including transaction costs, earn-out payments or adjustments; (3)changes in the fairvalue of contingent consideration and bridge financing costs; (4)cost reduction and

integration- related initiatives such as separation benefits, retention payments, other exit costs and certain costs associated with integrating an acquired companys operations;(5)excess costs that will be eliminated pursuant to integration plans; (6)asset impairment charges; (7)amortization of intangible assets; (8)inventory step-up recorded as part of our acquisitions; (9)non-cash interestexpense; (10)litigation- related and other contingent matters; (11)gains or losses from early termination of debt and hedging activities; (12)foreign currency gains or losses on intercompany financing arrangements; (13)andcertain other items that the we believe do not reflect our core operating performance; (14)the cash tax savings from acquired tax attributes; (15)the tax effect of the pre-tax adjustments above at applicable tax rates and certain othertax items. We define adjusted gross margin as total revenues, less cost of revenues, adjusted for amortization of intangible assets; certain upfront and milestone payments to partners; certain cost reduction and integration-related initiatives;inventory step-up recorded as part of our acquisitions; certain excess costs that will be eliminated pursuant to integration plans and certain other items that we believe do not reflect our core operating performance.

Our presentation of EBITDA, Non-GAAP earnings per share and adjusted gross margin may be different from non-GAAP financial measures presented by othercompanies. Webelieve that our presentation of non-GAAP financial measures provides useful supplementary information regarding operational performance because it enhances an investors overall understanding of the financial performance andprospects for future core business activities by providing a basis for the comparison of results of core business operations between current, past and future periods. Management uses non-GAAP financial measures to prepare operating budgets andforecasts and to measure performance against those budgets and forecasts on a corporate and segment level.Endoalso uses non-GAAP financial measures for evaluating management performance for compensation purposes. We have not providedquantitative reconciliations of projected EBITDA, Adjusted earnings per share or adjusted gross margin because not all of the information necessary for quantitative reconciliation is available to us at this time without unreasonable efforts. This isdue primarily to variability and difficulty in making accurate detailed forecasts and projections. Accordingly, we do not believe that reconciling information for such projected figures would be meaningful.

Endo Contacts:

Investors/Media: Keri P. Mattox, (484)216-7912

Investors:Jonathan Neely, (484)216-6645

Media: Heather Zoumas-Lubeski, (484)216-6829

Par Pharmaceutical Contact:

Steven Mock,(201)802-4033

TPG Contact:

Media: LukeBarrett, (212)601-4752

Media Contacts:

JoeleFrank, Joele Frank, Wilkinson, Brimmer, Katcher, (212)355 4449

Andy Brimmer, Jo Joele Frank, Wilkinson, Brimmer, Katcher, (212)895-8611

# # #

EX-99.23d928010dex992.htmEX-99.2

EX-99.2

Exhibit 99.2

Endo International plc

Par Pharmaceutical

Acquisition

May 18, 2015

2015 Endo Pharmaceuticals Inc.All rights reserved.

Forward Looking Statements

This presentationcontains information relating to the acquisition of Par by Endo that includes or is based on forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, Section 21E ofthe Securities Exchange Act of 1934, as amended, or the Exchange Act and Canadian securities legislation. These statements include statements regarding the timing and the closing of the transaction, the expected benefits of the transaction, theexpected accretion to earnings resulting from the transaction, expected product approvals and Endos plans to operate Par. Forward-looking statements include the information concerning our possible or assumed results of operations. We havetried, whenever possible, to identify such statements by words such as believes,

expects, anticipates, intends, estimates, plan,projected, forecast, will, may or similar expressions. Wehave based these forward-looking statements on our current expectations of future events. Because these statements reflect our current viewsconcerning future events, these forward-looking statements involve risks and uncertainties. If underlying assumptions prove inaccurate or unknown, or unknown risks or uncertainties materialize, actual results could differ material from thoseexpressed in the forward-looking statements contained in this presentation. Risks and uncertainties include, among other things, uncertainties as to the timing of the acquisition; the possibility that various closing conditions to the transactionmay not be satisfied or waived, including that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the transaction; that the FDA or other regulatory authorities do not approve any product(s) in the mannerdesired by Endo on a timely basis, or at all; that there is a material adverse change to Par; that the integration of Par business into Endo is not as successful as expected; the failure of Endo to achieve the expected financial and commercialresults from the transaction; other business effects, including effects of industry, economic or political conditions outside Endos control; transaction costs; the outcome of litigation, actual or contingent liabilities; as well as othercautionary statements contained elsewhere herein and in Endos periodic reports filed with the Securities and Exchange Commission (SEC) and with securities regulators in Canada on the System for Electronic Document Analysis and Retrieval(SEDAR), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K. We do not undertake any obligation to update our forward-looking statements after the date of this presentation for any reason, even ifnew information becomes available or other events occur in the future, except as may be required under applicable securities law. You should understand that it is not possible to predict or identify all such factors. Consequently, you should notconsider this to be a complete discussion of all potential risks or uncertainties.

2015 EndoPharmaceuticals Inc. All rights reserved.

1

Non-GAAP Financial Measures

This presentation mayrefer to non-GAAP financial measures, including EBITDA and adjusted gross margin, which are financial measures that are not prepared in conformity with accounting principles generally accepted in the United States (GAAP). We define adjusted grossmargin as total revenues, less cost of revenues, adjusted for amortization of intangible assets; certain upfront and milestone payments to partners; certain cost reduction and integration-related initiatives; inventory step-up recorded as part ofour acquisitions; certain excess costs that will be eliminated pursuant to integration plans and certain other items that we believe do not reflect our core operating performance. Our presentation of EBITDA and adjusted gross margin may be differentfrom non-GAAP financial measures presented by other companies. We believe that our presentation of non-GAAP financial measures provides useful supplementary information regarding operational performance because it enhances an investors overallunderstanding of the financial performance and prospects for future core business activities by providing a basis for the comparison of results of core business operations between current, past and future periods. Management uses non-GAAP financialmeasures to prepare operating budgets and forecasts and to measure performance against those budgets and forecasts on a corporate and segment level. Endo also uses non-GAAP financial measures for evaluating management performance for compensationpurposes. Reconciliation of non-GAAP financial measures to the nearest comparable GAAP amounts have been provided within the appendix at the end of this presentation.

Additional Information

This presentation isprovided for informational purposes only and is neither an offer to purchase nor a solicitation of an of fer to sell shares of Endo. Endo and Par shareholders should read any filings made by Endo with the SEC in connection with the proposedcombination, as they will contain important information. Those documents, if and when filed, as well as Endos other public filings with the SEC, may be obtained without charge at the SECs website at www.sec.gov and at Endos websiteat endo.com. 2

2015 Endo Pharmaceuticals Inc. All rights reserved.

Par Pharmaceutical Acquisition: Overview

Endo toacquire privately-held Par for $8.05 billion

$1.55 billion in equity to Par shareholders

$6.5 billion cash consideration

Fully committed financing from Barclays and Deutsche Bank

Expected to be financed by combination of cash, term loans, bonds and an equity offering of ~$1.5 to $2 billion

Creates leading specialty pharmaceutical company with top five generics business as measured by U.S. sales1

2014 pro forma revenues of $4.2 billion

Unanimously approved by both companies Boards of Directors

Par CEO Paul Campanelli joins Endo to lead Generics business

Expected to close in 2H 2015, subject to regulatory and other customary closing conditions

No shareholder approvals required

1 Source: IMS Health LTM as of 10/31/14


3

Par Acquisition: Significant Value Creation

Diversifies product portfolio and R&D pipeline

Capabilities

Expands manufacturing and technology capabilities

Growth Accretive to existing growth profile: expected to drive double-digit organic growth

Profile Revenue: double-digit CAGR for pro forma revenue in the near- to mid-term

EPS: expect adjusted diluted EPS to grow faster than revenues

Accretion Accretive to adjusted diluted EPS within first 12 months with double-digit accretion to adjusted diluted EPS in 2016

Operational and tax synergies of $175 million

Synergies

Strategically preserving R&D pipeline

Transaction multiple of 10-11x 2016 adjusted pro forma EBITDA

Transaction on a post-synergy basis

Multiple Anticipate returns well in excess of cost of capital

Enables de-levering to a projected 3-4x net debt to EBITDA in 12-18 months

4

2015 Endo Pharmaceuticals Inc. All rightsreserved.

Compelling Strategic & Financial Rationale

Strategically expands product portfolio, R&D pipeline, capabilities and long-term growth drivers

Adds extensive range of dosage forms and delivery systems Focus on specialized, market leading products

Designed to accelerate Endo growth:

Double-digit revenue growth in mid-term, accretive to adjusted diluted EPS, meaningful synergies, increased generics adjusted gross margins Strong R&D pipeline capable of fuelinglong-term organic growth

Drives strategic expansion of overall corporate profile, scope, and size,establishing a powerful platform for future M&A

Strong cash flow expected to lead to rapid de-leveringback to 3-4x net debt to EBITDA in 12-18 months

Aligned with Endos strategy of pursuing accretive,value-creating growth opportunities

Creates shareholder value and drives benefits for patients & customers

5


Transaction Aligns with Endos Strategic Direction

Build a leading global specialty pharmaceutical company

Focus on maximizing the value of each of our core businesses

Participate in specialty areas offering above average growth and favorable margins

Transform operating model to maximize growth potential and cash flow generation

Continue our commitment to serving our patients & customers

Improving lives while creating value

6

@2015 Endo Pharmaceuticals Inc. All rights reserved.

Endos Execution of M&A Strategy Is Driving Value

Expanded Generics platform

Expanded Genericsplatform

Sharpened strategic focus on pharmaceuticals

Branded Generics

Intl

Boca

Aug 2013

Sumavel DosePro

Apr 2014

DAVA

Jun 2014

AMS

Divestiture Mar 2015 Q3 2015 close

Par

May 2015

2H 2015 close

Paladin

Nov 2013

Established

Endos global presence

Somar

Apr 2014

Strengthened intl platform

Auxilium

Oct 2014

Rebuilt Branded platform & pipeline

AspenPortfolio

May 2015 Q3 2015 close

Transform Gx business; Drive long-term double-digit growth; expand corporate M&A platform

Note: Dates represent first public announcements of transactions

Additional transactions include: HealthTronics divestiture (January 2014), Natesto licensing (November 2014)


7

Endos Vision: Leading Specialty Pharmaceutical Co.

U.S. Branded

U.S. Generics InternationalPharmaceuticals

Transaction closed January 2015

8

Generic Pharmaceuticals: Current Landscape

USGeneric Pharma Market ($B)

120 100 80 60 40 20 0

2010A 2011A 2012A 2013A 2014A 2015P 2016P

Substantial market opportunity for growth of generic products U.S. generics market growth expected to be driven by:

Aging population

Regulatory focus on increasedaccess to drug benefits Role in healthcare cost containment Increasing scripts conversion vs. branded at 80-90%

Consolidation and maturation of competitors have stabilized the pricing environment Basis of competition shifting toquality, reliability and specialized capabilities

Benefiting players with commercial, legal andentrepreneurial savvy Specialty generics growing faster as a segment and securing higher gross margin

Source:Par and EvaluatePharma

9


Endo+Par:CreatesaTop5GenericsPlayer

U.S.IMSGenericsSales

($ inbillions) $10

$5

$0

[1]

PF [2]

GEP[3]

Source: IMS Health LTM as of 10/31/14,Wall Street research.

[1] Pro forma for acquisition of Par

[2] Pro forma for acquisition of Ranbaxy

[3] Pro form for acquisition of Hospira

10

About Qualitest

Founded in 1983 Acquired by Endoin 2010 Headquarters: Huntsville, AL

Manufacturing Facilities: Huntsville, AL & Charlotte, NC 1,750employees

Double digit organic growth performance and outlook

Strong volume growth across balanced portfolio of over 700 products

Controlled substances, specialty generics, Liquids / semi-solids, commodity generics

Pipeline of approximately 90 programs Strong expertise in controlled substances

11


About Par Pharmaceutical

Founded in 1978

Headquarters: Woodcliff Lake, NJ

Manufacturing Facilities: NY/CT, MI, CA and India 2,000 employees

Privately-held pharmaceutical company operating in the U.S. as two business segments:

Generics : approx. 95 products with 215 pipeline programs

Multiple dosage forms and delivery systems with a focus on high barrier-to-entry products, Paragraph IV, first-to-file and first-to-market opportunities

Branded : 2 approved, marketed products

12

2015 Endo Pharmaceuticals Inc. Allrights reserved.

Endo + Par: Broad Facilities Footprint

2.7m sffootprint establishes leading generics player with capacity for additional growth

Endo facility Par facility

13

Par: Evolution from 2012 to Today

2012

2014

Revenue ($mm)

Adj. Gross Profit Margin

# of ANDAs on File

Filed Market opportunity ($bn)

# of Technologies

$1,050 47% 85 $21bn

8

$1,309 52% 115 $37bn

14

14

Par Today: High-Value, Long-Term Growth Products

Focus of core business is attractive high-value generics

Paragraph IV, first-to-file and first-to-market opportunities

Specialized products that are difficult to manufacture and/or present complex legal and regulatory challenges, includingthe generics of:

Lovaza (complex and difficult-to-source API) Precedex (unique dosage form) LuvoxCR (controlled-release product) Focalin XR (controlled substance)

Emphasis on market leading products

Majority of Pars top 10 generic drugs by revenue are market leaders

Significant number of products are either exclusive or have two or fewer competitors

Current product base is relatively more profitable and longer-lived than competitors

Lovaza is a registered trademark of GlaxoSmithKline; Precedex is a registered trademark of Hospira; LuvoxCR is a

15 registered trademark of Jazz Pharmaceuticals; Focalin XR is a trademark of Novartis AG

Par Snapshot: Extended Release Products Leader

Generics Extended Release (ER) market size: ~$10 billion1

Key market drivers: High barrier to entry Difficult to manufacture

Par is one of the largest suppliers of ER products

13% generics ER market share for Par in 20141

In 2014, Par offered 6 of the top 10 ER molecules, with two more in development1

Key Par ER products and 2014 revenues include:

Buproprion HCl ER - $84m Propafenone ER - $76m Lamotrigine ER - $41m Fluvoxamine ER - $24m

1 IMS data for year ended December 31, 2014

16

Par Snapshot: Injectables Products Driving Growth

Generics injectables market size: ~$20 billion1

Key market drivers: Difficult to manufacture High regulatory scrutiny

Par injectables capabilities rapidly expanding; goal to be leading generic injectables provider within 3-5 years

Par entered the market in 2014 with acquisition of JHP Pharmaceuticals Currently markets 8 generics and 12 branded products 15 products filed and 20 more in development

Par injectables net revenues in 2014: ~$140 million

1 IMS data for year ended December 31, 2014

17

Par R&D Strategy: Building a High-Value Pipeline

Par has a full suite of high-value, high barrier to entry product technologies in development, including:

ER oral solids Injectables Topicals Nasal sprays Ophthalmics Films

~60% of filed ANDAs (115 total) are alternative dosage forms ~70% of R&D pipeline (100 total) consists of alternative dosage forms, including:

32 potential First-to-File opportunities 6 potential First-to-Market opportunities

18

Endo + Par: Expanded Internal Generics R&D Capabilities

Technology

Dev. Programs

Oral Pre- Cont-Oral Topical Nasal Ophth- Sterile

Solid filled Patch Film API rolled NDA ANDA CRO Solid IR / Liquid Sprays almics Vials ER Syringe Subs

+ Capability development in process

19


Endo + Par: Drive a Diversified R&D Engine

Endo Filed ANDAs (50)

Par Filed ANDAs (115)

14%

6% 28%

6%

10%

0 18%

0 0 18%

18%

42%

11%

29%

Immediate Release Extended Release Injectables Topical Sprays/Nasal/Subling Ophthal Film Other SoftGel O Cs Liquids

20



Endo Pro Forma Filed ANDAs (165)

Liquids

OCs

Topicals 2% 4%

Soft Gels 5%

0 0 2% Immediate

0% Release

38%

16%

Other

8%

Injectables

25%

Extended

Release

21



Endo Programs in Development (52)

Par Programs in

Development (100)

>75% of Par Development programs are Paragraph IV / First-to-File

10% 4%

0 6%

6% 50% 2% 6%

0

17%

2% 5% 5%

3% 27% 9% 25% 24%

22



Endo Pro Forma Programs in Development (152)

Liquids Topicals

3%

Soft Gels 8%

1%Films 1% 1%

Ophthalmic Release Sprays / 5% Nasal / 35% 3% Sublingual Other 5%

16%

Injectables

22%

Extended Release

HALF of all Development programsare Paragraph IV / First-to-File

23


Endo + Par: Significant Generics Growth Potential

Net Revenues ($000s) Pro Forma

$2,500 $2,000 $1,500 $1,000 $500

$0

2011 2012 2013 2014

Par Endo (Gx Only)

Adjusted Gross Margin

($000s) Pro Forma

$1,400

49%

$1,200

$1,000

$800

47%

$600 $400 $200

$0

2011 2012 2013 2014

Par Endo (Gx Only)

Adj Gross Margin expected togrow from high 40s% to low to mid 50s%

Source: Companies SEC filings, 2011-2015

Summary:

Financing Structure Provides Flexibilityfor Future M&A

Attractive de-levering profile

Strong cash flow leads to rapid de-levering

Expect to be back in the 3-4x net debt to EBIDTA range in 12-18 months

$8.05 Billion Transaction

$1.55 Billion Equity$6.50 Billion Cash

Consideration Consideration

Cash

Par Shareholders Term Loans

Bonds

~$1.5- $2B Equity Offering

Fully Committed Financing

25

Par Acquisition: Significant Value Creation

Capabilities Diversifies product portfolio and R&D pipeline

Expands manufacturing and technology capabilities

Accretive to existing growth profile: expected to drive double-digit

Growth organic growth

Profile Revenue:double-digit CAGR for pro forma revenue in the near - to mid-term

EPS: expect adjusted diluted EPS to growfaster than revenues

Accretive to adjusted diluted EPS within first 12 months with

Accretion double-digit accretion to adjusted diluted EPS in 2016

Synergies Operational and tax synergies of $175 million

Strategically preserving R&D pipeline

Transaction multiple of 10-11x 2016 adjusted pro forma EBITDA

Transaction on a post-synergy basis

MultipleAnticipate returns well in excess of cost of capital

Enables de-levering to a projected 3-4x net debt toEBITDA in 12-18 months

26


Summary:

Endo + Par: A Leading SpecialtyPharmaceutical Co.

Spec Pharma Landscape by Enterprise Value

($ in billions)

$100 $167 $103

$75

$62

$54

$50

$44

$33 $28

$25 $20

$12 $9

$8 $6

$0 PF

Source: FactSet. Note: Market data as of 5/15/15.

27

Summary:

Endo + Par: A TransformationalCombination

Company

Size and Scale

Generics

(2014)

Generics R&D

Pipeline

Long Term Growth

Drivers

Enterprise Value:

~$20bn 2014 Revenue:

~$2.9bn

2014 Revenue:

~$1.1bn (+56% from 2013)

~90 programs

6 ANDAs to be filed in 2015

Expansion of branded and generic portfolio and R&D pipeline Continued investment in M&A and licensingopportunities

Enterprise Value: n/a 2014 Revenue:

~$1.3bn

2014 Revenue:

~$1.3bn

(+19% from 2013)

215 programs 115 filed ANDAs

100 programs indevelopment

Strong performance from portfolio Attractive R&D pipeline Focus on specialized products withhigh adjusted gross margins

Enterprise Value:

~$28bn

Pro forma 2014 Revenue:

~$4.2bn

Pro forma 2014 Revenue:

~$2.4bn

~300 development programs >100Paragraph IV,

FTF or FTM 25-30 new ANDAs per year

Top five in U.S. Gx sales New Gx capabilities

Operational synergies

Double-digit growth

Transformative platform

28

Appendix


Reconciliation of Par Non-GAAP Measures - EBITDA

30


Reconciliation of Par Non-GAAP Measures EBITDA (continued)

31


Reconciliation of Par Non-GAAP Measures Gross Margin

32


Reconciliation of Endo (Gx Only) Non-GAAP Measures Gross Margin

We define adjusted gross margin as total revenues, less cost of revenues, adjusted for amortization of intangible assets; certain upfront and milestone payments to partners; certain costreduction and integration-related initiatives; inventory step-up recorded as part of our acquisitions; certain excess costs that will be eliminated pursuant to integration plans and certain other items that we believe do not reflect our coreoperating performance.

The table below provides reconciliations between our U.S. Qualitest Pharmaceuticalsegments adjusted gross margin to gross margin, which is determined in accordance with U.S. GAAP, for the years ended December 31 (in millions):

33


Endo International plc

Par Acquisition

May 18, 2015


GRAPHIC4g9280101.jpgGRAPHIC

begin 644 g9280101.jpgM_]C_X``02D9)1@`!`0$"6`)8``#_X@Q824-#7U!23T9)3$4``0$```Q(3&ENM;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@ML![\'T@?EM!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".0F/":0)MN@G/">4)^PH1"B@2!Q(F$D429!*$$J,2PQ+C$P,3M(Q-#$V,[email protected]$\43Y10&%"!6;%;T5X!8#M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9M11EK&9$9MQG=&@0:*AI1&GZ1\3'SX?:1^4'[\?ZB`5($$@M;""8(,0@\"$2M.P]*C_9_GGNO'&H7-Q(TLLUJ6D=C\S$N,DUD_'+_`)*/=?\`7"+_`-!K2_9SMS_PE]Y_UY?\`LXK@I8NO6XJ4:DVU&;25]%;:R.NI0IT\DYH12;BK_.S%^.7BM#5E\6'2H+R6WM;6-'À/]1M5O;E8"D8,2S,$(,:Y&W..:ZS]G#/_``CÎ8_YÂ_Z`M4OMBQX&U._U^_\`$%O'Q3_>>T32>Z5R:1M^T=,(Q)`K9^'OB#7-?LYIM:\(7GAYEV/`LU[;W2W","0ROM"[`$8Y!QU&"1S7G?P7\`>//#7@/Q'?\`BJVT/Q!XNU2*WL%MYKEA9W5E:PK#M%'(YC8J9`9G;Y"-TO((I/A;X/^(/@O1/&%]X;\/:3HXO883X-_'&D:5HL'AK2[FQTÛL-1:[:\FN&B\R=MF,:;(PL*A4(+98DXP*`)?AS\7[GQKX?NO$&C_#SQ*^CP6LK07+&W#WES')Y;M6\,9D!;G/[PXCRK#=Q6IX%^(5YJWCJX\'>(O".H>&]8CTX:G;PW%S!OHN'?XD_1'Y_P`>_P`"CZO]##KZI_X)V_\`(K^)OÔZ'_T6:^5J^J?^"=O_M`"*_B;_KÂ_]%FO4SK_1CMV4#)/Y"@#B;#XP_#F[\30Z#;^(U>XN;UK"WF^RS"TGN5)!ACN2GDO)D$;5*?XR^+WP[\*>(9M$UWQ&EO>6HC-YLM9I8[$2?E`'NGCGXM_#[P?KLFC^(/$*VUW;Q)-=K':S3+91OG:]P\:,L*G!(,A7MCGIS5[Q#\1/!6A:Q::7JFOPPW-['%)%M21XUCED\N)Y)$4I&KO\`*K.5#'@$MUYY\(SITFC_&I]7,)D/BO4EU'SL?\>XLX1&'S_!Y.,9XQG%$]#TW4]*%D9;^_>!RUK#9OO`6642B,[E8*/GXP:`/I23Q%I*M>,H?"@N6;5I;)KXVZ1LWEP!PF]V`P@9B0NX@L5;&=K8V*\&^&GBK4_#7BR_?M7-"AOKO6O%%MI'B+6HKW#1:A+;I)%;PPE,FU@66*$,7#$EWVGE?$M236=-&D:KH'B#PW\4`%_P#/M[X/OX5'U?Z%"OI/_`()V?\AGQ7_UPM/_`$*:OFROH+]@M=;;M5?$W]B3:?$WE6OF_;87D!&Z7&W8RX[YS[5Z^;_[E/Y?FCY?A/_D;TOG^1];4M5S?E>/?^?WPY_P"`_P#/[X&Z4H"LK>8Q.\$DY]57&."1=F91\^W/R$\(#EVYKMT*@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHHM`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`MHHHH`\@_;6\`>(_B-\$VTCPM%#=:A9ZG;:@+">0(E^D3$M"6)`YW9&2!E1R.MM>8?'X?&?XM_">'PWI7P7F\-6.FWEK%O$D*Z)\+;CQCX?N+,>=+IU_$EU!/N8,K0RD!T*;)?L&]'M^%'BOX8W5A::!#/'+XC&HQ/:S*'9T\M!EF+%\=L`9..@^@**`/E?]I+X0^.]M%/'\.F0>*[E9(U6V%K^)-SDHMAM;>:WC:-W5F!YZ87/-7OVLO"7B3Q3JOPWD\/Z3+?)HWC2TOM0*.B_9[=`VZM0[F&0/;)]J]=LK>"SLX;2UA6*""-8XHT&U411A5`[```5/0!XS^VUX1\2>,_MACH^F>&-*EU*[M_%&GWR44`>.Z#\3?BUKNL6.GP?`MC5-'1[F)=0OM8UFW6"VBWCS&01[FE8+NV@`9.*9XZ$^)+W]M3P+XQM=)FDTM+2_#]];7E\'0+#(^[8A!;L-R)';98XU9RHR,MC`SR:`.JHKF%^(/@M_`M\'C-/$NGR:!201(N1T)D8+@]#UQ5'PC\5_ASXJ\73^%_#OB_M3=1U:W5V:VAD),BHI6OMA3PO;>'5\/P>&])BTE75QI\=C&MN&5@P;RPNW(8`YQU`-7;[3=/OKBUN;W3[M6YFL9?.M))H59[>0J5+H2,JVTD9@D4`?-_AR?Q-9_M1_%*VB\-%DY5*]4TB#4-8FBE:VNHII]L3LN,1L8MG2(`$@!0>:`/7J*\Y\6?-!U[Q%IYCZO?:=>:GIUO=3Z3./.Q&;J0NXXK+U+X5_$CX5*OPPUCPG\+]'M\-:#)XEM?[/U6YN(I%Q;&.1#(HC&9)E\PD;R,Y.6KH_$'PR\%>(O#6DZ+XF\M/V>L1:+`D5G+"[SP/_P`(=W#0J[2-(74?PMO9FW#D$DMUTU%`''Z-\+OA]I7AV^T&P$:;'IÎ2QRWL)C+?:7C8,C.S$LQ5E!&3QCBM_M5M%TK5-0TZÔ[""XN-)N#N-\??"OQ#>_%35O%=GH_@;Q/:ZI8VUK;VOBJW=FTD0JP*0ME4D4QN6+L,*=Q/)&,>T44`>4^"_@3X0MOACHGACQEIMAXBN=&6?R[EH6C6$3M2M(\,(#;D@7%--TV>V21(YH(`)`LFS>"Y^9L^7'U)X0`=*ZRB@#B8/AM)\-(/%O_``DT/@K28]4%U]K$ZP8`GZ^Z'`^4Y%8GA'X4?#GPMX@76_#W@_3-/OX]XAG@BQY`)9WP'(Z7XXMKSQ&ND+83*[3/%O++MMRN>?7M76Ù@V?@_1;36%U.&*7[0LC2`F5B-S9SQ^)K?Q[UY&3T\SA3G_:$DMWS/EM_+TOYG5BI89RC[!-*VM^XM>2_M+>--6\,:MX/TBW\21>$M*\1:A-;:EMXDFMDF%B4BW11#S08D:5_E#R`@;3QDUZU7$?KTRS@T[4_AUJ_BW1-2CD2M]73[2*\$)&W:LMN[!G5LM\RAL%>0,@U[!RF+XLNM?\*?"$3Z[\2[B:9M8LTMMM>LM$@:62&:YA2.)X@3&V\N4,BA?E;%M3TW3=M0\;Z?J/AWPW/*LEQI=@EY:NX8!B(US'-)Y88[%..M0^,K+Q+X@^,'Q2MM#M/M%EWH-[):Z?K0\,R:>JW`6SC$D+&[*NMP$/;]D5UM5BCD!.0V(G7O]T\US_Q$\&^*KSP3\:;6ST"\MFFUWQ%8W&EQH@S>QI#8AG3GD`QR`Y_N&@"[\2/%6I:OÛ-I'@5I/'=CI5CIPMN'_L2V>%+JY>XB59I9%&7M40LK'[H8D'.*ZCPG\2M&T3X-6'B;6_$FJ>(O[0MU2XL;&0:2([W4)_M,T:V\5O$/F9?+90>ZIN8CDU>DTC53Û7!X@&GS?V6O@NM2S-Y@>6)S>QN(\Y^]M!;Z"O+]%\)>,O#_P`,OAMXB'A34+ZZ\&>)]4O-2T6$M)]K>VN9;N,2Q(S`.ZK,D@7()4G'-`'K-K\4=*F\)7&MOX$-M=D\$ZYX;TWP9;7[WMQJZ1QF>YN(EA$$.QV\Q``SF0?*V^H"*VN\1[I&OIID5R.`'&WGT?)H`[/PC\:/"VN^(M+TF33/M$6C_`-O;O[%N]8TB2UM]4(3?MB=OXB@+!7"D@:S#'%#;_9T?]S`RNWGL[L%#*-H7))YQ7)ZII_CO1?@7X^^M#MK\.=ZDEF65IB^1*!*5\O;N+*`.#D`'MW@_QEITMVL:+X.N9[F36[KPU%K#,T9*/#N2-F+_WR[=/QJ"Z^*_@VT\*:]XCNKRXALO#MVL2Z-=YMG:26[C=4\J&-06D9G=54*/F)KB-9A\1>#/BQX2\;_P#"'ZYKFGMXM+.A7L6DPI+AH`[/XH_',Z%\'O$'B?1_!_B.WUM;1Q&!8ZUHTT*Q^8&*2RD''DG8P+JQPV`7IT>LQQVTU_+]]D2+_MFMYXB"05DC894@@_P`QD'/"FK74.K:-XH73M.F6&_UJ/19M3I]HS;>7E(&5&]ZEJ%U)5L\_T\S]WOQY>[C=7:>$=,M=*\&Z9HUC;365K8V$-MM!!))OD@C2,(J,V3EE``)R27"MQW;'2TA^4YZ"0%23CD5!%[CQ!KUTT%E;%5)2-I))9'8(D:(H+.[,RJJJ"2M2*Y7]F?1=4T+P/JMKJ^FRV-Q/XHU>Z5)5"L\4E],\;\=0R%2#Z$54_:N\*:WMXJ^'=@=`MKJ\N]#UVSU9K.SN_LUS=1PR$ND,N0$EVL60DCYE'(H`M6?QC\/RM6.M->:'XFTW4-!TWÛ+G2;W2FCO);3)!FAC!(E4$$':201@@$@'6L/B5X2O]M>TW3--U$WC:GHAUQ+B%3WP*M?`[Q5XDET#0?!FJ?#3Q)H]MUI>EK::G>720K8P/#$$'DRAR9@[*-NQ>`&`*\[C@UJXUV*:XT_3].TUMI;J6VBE,37!0D!(BP&UW8;MRXR3BN4_:?\,>.(_%5GXD^'>DS7M_XBT2X\)ZMJT3*OV..=E>"];)'$+&8G'/[RLOXA?#RX\)_%'1M6L-,\977A:#PG;ZÀ\(WMKQ7=B]O(S)YD^N(O$,_FWTTKD!IM9"7Y0&HM>^%OB?2/A[\M.M:>QUS4-0T;4+W4_%5OH-Z;;4GFU!'::2%PR[VCDZM"Z[T+(.-3N-6COE\7>(I=6B1(#M&;9''$;$L=Q'J,?2@#@_V>$)[>PBGC9I((EN%VBYBJ1G)QZQX!U_Q/M\1?`>OSZMX+O?"D%YYMKI,&IN!=3Q-%M\Z:,?ZK+LV%R3@9[UZ'10!\Y_L0^M)];\.^"]"^#GB+X>>+--U;1!=1W>H3:>1IRH)))$?SRPD2&,".>V/S$-E@3V*X(YKC_VM4?#5R/V@O%WC?POX'U;P3X%U/3(8(--U&W^RF]O`X9KA+;/[M0NX=OO)]:U"?2OA3KM'A338;>/R=2U33([&2^9F.42$?/M4`'SO7V97F>I?"^ZU7]IO3_BCJMNLPSV.A:0UEHÊ"W(,$TA/F3,Y;!)5B``H[J44`>4_$#2M4N/V,]1T:#3[J74F\%>0MDD+-,9?L@7RP@&=V>-N,MYH^'.E:I;_L9Z;HEQIMU%J2^"_L[63PLLPE^RE?+*$9#9XQUS7JU%`'S-X9^M%FO>-?\`@G'I/P_ELIM+U]=-$MO;7\;0/'/'O$W=_HM5&VLDDA$:,I[$,X(Ê>7?#CX.:GKOPRTKM7;OXD^-+/5+^Q2Y(34V:*-G&X?*?F(P1_%^-:O[=-W-)\-]+\-6A_P!)\0:QM#`B9^\!DX_[[\NN,^+Î?&GP7X4T_3_$NLZ;8^&KATL;B]T"W)FMH]N,?O-IM!VJ-_B)XV8;AJ6MFU@?_IG$6(`/M^ZZ?E4OP=\/ZS\*/V>=?OM>$=M>8NM2%I&^Y+3,0"Q`Y(SE!G!/7OUKE/!^MMW/PT_8CAUFS)CU;69'^SOCE9)I&57^HC72]M=-20/'9O)MMCB0G)!.XKD`G@`9SFIJ8."7+%OFNDKVU^70UP^;5I2YYQ7)9MV3]VRO9MZ-MOR/3O&/Q/\!>%M673=?\3V-G=MC,+.69M87:,^CA0=OXXKI]#U73]:TJ'4M*O8+RTG7=%/!('1Q[$5\Y_#G4?#GA[P,FBM:5\&?%&NZO-%_IEQ?Z($%U,WWC)+(257).!@X'ODUZ3^RKX(UOP-\-I+'7@DM-W?7TEV;..3XE32-!TJ*/4M!#(5,R'#F'(Z!FD`/LK5M*G3K-*4M8IMM?@O,XZ-;$8-2E2@^6I-*$6W=*VKMUU2ZGM_@?QQX3\8R7:>&=ME?9+KI:/?V]]9S#,V7P5\.1ZAUTWQ=ILT]O&\KQ^9M.Q069EW`;@`"3MSP,UTGAG6M*\0MZ#!K.C7L=Y870+0W$?W7`)4D9]P1^%>,?M6;PQ:;M);0K%(CLX!&Y0"1MWY!SG&>O-5_C#JFH^`_V7_#/A'1F:'5=8AMM,1D.UD+)MF4@CH23MS_MYH6%IU(Q=-M-NVOXLJ69XC#U*DI'XFM(0I>RG[*]W:.OF^GWM'/6KXEXFC]9244G-VOI9=;[[GLOCCXA^"O!TRP^)/$ECI\TBY6&23,A'KL7+M8]\8K0\'>)]`\5Z6-2\/:O:ZA;9VE[>0-M;^ZPZJ?8X-?-WP-US1].T637=>M^'/BSQ5XJUJ1KBYOSH9FC:.O+JIRY)*5MFM8XBE[:E*G>UTU]YR?P.T*3PU$_#^BS1-%/;6$?GQMP5D8;G!]PQ:KGQ4T.;MQ+\.-_99T+6K?6O&WBKQ!I=SI]UKMVM,T,5U$4?R4+%2`>=O[S'_`:]BI.-N.GTI>*YZM5U9N35O^`=^#PT%[[3;SPMX.7Q%I>UQJ444I6X1LKLV`9X^]GY6[=.M>>>M/O$_Q,^*WA^7P;H'PXU+P_;:CA+[4=9)C6.+\SW&`-K,B\J"Q/R]F:M$_CWXT\62?#'7]8_M2X^S6M&O"TEC%J>L63644M]GR8UEPDCG"MDA&8@8Y('3K6SX!\/V/A3P3I7AG3%VV>MD645I#QC*QJ%R?@^$O#VGZQJGBN]GM84O[]K6*+RH&E)+JCGD*>U9V@?%?Q'MI7Q!TGP;\4O!4?ANZ\0,T6C:G8:D+VPO)E7/=(;E&`$.&QMYY'->0>"/C=XAN_AMGXF^+&L^(?"S:3:VE_)IGA>!-EY&\,KI;^9,926,@B8[1&,[@5Z8(!]%T5XSM\+_%GQ,O?#WAK5+WQ!X'\11Z_J,ÒOLK&R.F0O`9'AB&^3SYE)7"G:5)4LH.0#M.,]WEBNN:@?LXFFMX7D?R("-\D8*8\QMJGM/R[@,UWGQ(\5:7X)\#ZGXIUEV6TTV`RLD8R\S#]"\:Z(FD^(KM>YFM(YUN%6WOYK9MZ@@'?"Z,1ACP3CVX%=!10!Y_X!^#'PZ\%WT]SX=T.>V^MTV\EO-%)J=S/"Z2D&0&*21D)8CD[.U>H44`8/B#PGHVM>*=&U[4[>2XN=`>673TM:5O)BED3893']UI%7(M*EGN5MC9RO!>S6XMNK8MN,$PB=1-%NR=CY')XY.>SHHÌWEO*NCRVFF-':RBW:.U81@K"VW"G;TPM#CCVKY-A^"?B-OAFWA&?X':4?&4D4B/XZ_MV%$^TNY)O@R$7`8,=X0)Q@+TKMZ^HH`X'Q)$O"WBFPT.3Q;#BV26T>M6UY-9WC850Y\V%U?:S`L5)(R:ML6_PI\"0_#N^\##1'ET34YQ/?0S7L\DES(&1O,>5G,A;,:#[75K;PYH,=C'KD:)J(6:1C5&HPJ[F)8X'%M"U_6-&U75K$M7%YX?NVN],E\UU^SRM&T9;"D!LH[##9'-.TOPOH>G>+-6\365CY>JZXD":AJ>'_$OAS7IIHM#U_2]2DM3B=+*]CF:(],.$8[?QKXYU+2['M1OV9_B%J.B:-IMG-77=L'+#6H='O_M`!!I=KJ-SCR+.>]C2:7/3;&6#-GV%>)?LY^Ò"6M?%3XH>*-;T*TU+4[/QS/M#927L2RK9A$@E#PJP(CK:UJ,RZE!$;:YL;KP];^%K+5;*>W`=I))9YMHV82!B&0JBXP.QYKS?6-`N;[XX?!WP%\2Y;37;?3_"EUA^%/#G[;7CC2_"5M:6EJOABREN;.T8>5;7#SRED5!QM%D;&*#`R^)-7ATB]&G:7)9RZ7Z6R+?6T1GJ*P]?^)GP[T+Q$OA_6?'/A_3]48@"RNMM3BCE!/0%6;()]Z\#\'^.-2L+K]HKQ[!H6I:)J%I9V5U#8:E&BW-O(E@X0R*KM,O4!Q@G@BO2OV>?A7X'M/@)HUIJ'A[3=8FU[3(KW6;N_M4GEU&>=!)(\KN"6MR7.,G@8Q0!Z!=>+=!M_'5AX0DOO^)OJ=C+?VMNL3L)((V17?>!M(O!.3GBMM#Q!JVEZ%I$VK:UJ-KI]A:KNGNKJ98XH@2`"SL0!R0.?6O(=0TZSTC]LCP#IM.FVZV]G8^!M1M[:%22(XDFME51GG```Y]*T/VZL?\,I>+LKN'DVQVÔÊ0\4M`==X9^)WPY\1:W#H_A_QWX=U34+@,8K2RU2*65PH+,516).`"3["C5/B?\-MM-\02Z'J/CWPW::E#)Y4MGHDE@G\Z(*S,Z(DG\:HC*@;H0HQQ6I!\2_AY-MXP_X12'QOH+ZY]H:U_LQ=1B-SYRYW1^7NW;A@Y&,\4`=1/)'#"TLKJB(I9F8MX"@(2.T2JQ)5"VQCMTW`CM4?[3GA+6_'7P-\0^%O#DT::E?0)Y*32&..?9(CM"[#HLBJR$^C6.>%)HI%DCDM4,CHP964C(((Z@BODGQ;XDM_AQXR^+&C2^"[3QW'K5Z^HW&L6\!N(]'\^-8QM:ZFP1C''&`7`343E\0.2*`/J&BO$AXP^+/A/XI>#;;QQ/X>N]'\IK)T_X?_%WPW+_"OA:Y\+_P#".^*M7N]3@UF]DF:[TW[3S+%]MG";96#9V,7`&$?$GA#X"_!3P5#J%E:>(-*\5:9:0W01KMBVCN%BGVL5.TNF>#T.">E=[X;\'_`!(\4?&C0_''Q'A\/Z9:^$K6YCTK3M'NMI;K[1UD7Q!XMOM7M?L[LV()O+VA\JM,/\`*2:;JW5Q!!$82,BX'RNN0!7NM%`'MF:^!?$\GQT\(^-=0U&QO(]&\+76F:E.JF*2XNI7@;S(X@"%0F-SC=QD#GK6AM^TKX/U;Q]\$->\(Z'):QZAJ4/OC7J?@WQ[XTAT'0]!\-:G+J-C8::9I;N[N8C)`K2/M(JB.+(9@J@EAMSCM]!44`>&>#O"'Q?\ÀNWB+1/"6E^$_$6E:SK-WJMI?:IJM4UK"=8\3>,OAYJFG36BP^%=>.H7XF=E9HOLMTL>(P%.6W.O!QQGFO0Z**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BMBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH;[M#T`;D&ES7DEUXAMUQ?&CVPU.X$0U#RQ'QMV^9C'3IBO65)(_"O"R?/:6:2JQIP/_9=\.?"JVDO?$GPD\9:AJ>EM7D"PW&G'69;NVAD#9$ABF)DBE(R#DC([5SG[,MO)XA\K_ÒXG:!\M1_'6F6%CI?Q2$EOJ(B@$2>&+R>8S00`D_+&X*JW3#*>63!VQJ"#TYYZ8->1>,/$_CC6/VI_@_I'Q`\&1^']6MT[4;^5)K.[Û6-]');8#128!#J4(9&&1E3T-:WQ6U&U\"_';X0_$SQ$[0>&$MT*?1KO4"I,5A-+$K1O(?X5;D;CV!]*K?$SXB>&/'G[6/PAB\(WIU6QTG5;Y)M]5MQNLI)Y+4GR(I>DDBK&6;;D*&7G/``/1O!NO:3,O#EOX1TNUU*ST"MQN;G7HO^/J]5SA8I/E^ZH`QR>@]!7*^'/CA\4/&MYXBTGX?_``NL[^\\.:U=MV5S>W^JFWLBD4A5$1BFYYG`)*C"H-N6^85;^';K_`,/"/B(H8;AX3TPEMI_[";JVB_$;:P;'Q$U4'!S@YCH`V/!?QXT74_P!G/5OBIJ^DW6F?\(\;B'5]M,#!Y(;J)@IB5L#.YF3!('WN>AKD_%_QG^-?A?0=#U_6?A?X9CL?$U[!9V$7_M``D4BRV\KD?B5\1?#G@:X\.PZW)2^._B9XPG^+EU\./AIX6TW5=4TFPCOM7O=7OWMK6T64GRXEV(M[/(P!/0`#UJ#X!?%GQ7XSO/%1\7^$]+\-V?A.>:SU"6+5S//`/A&\UO4+F86IT22ZCMI+:X$GER)+M*_RJL9R2P!)7!`YQ7`_L[_';X9^%OV?M'T3QAXBM/#NN>%;!-/U31;W,=Y'-M"-A5(2-S[MH(V@YW?6N%L;[QU\._V.9?$=L;SPNWC+QP]_?7:VVZXT/2[N7!MFV$'8VU$.2./,'0]`#UG3OBO\1O#?Q.\-^%_BGX(T?3;3Q=V#W%`%+_@H%?II?@_P)JM?9UOF**Q6&*-'8`%MNYR!D'L,UYM=HÊ_LUZSXL\,P0_%G6_$^H2:K;SZ3I\OBNZU`-GI7J'QY=5_;(^"JE@"W]L8&>3_`*,M`%[X?_%KQPGQMHLOAQ\4/!-CX?OM^'/CK\3TA\:^(/`]Y?:[B[M=+$-K5J\À18;K>MA;R;B0;F.>.5^4XX`/H#]E_XD^(_BCX-N_$>L^&;'1+9;IK>U2WU$W,C/&[IM,LJE%\ME=0,8?LEGX=Q?!VSTWX;:T^KZ;8S2)=W-P&6Z>Z9O,E:=M&5660LV06L(8*99Y51,DX`RQ`RM3Q0`W6-,T[5;7[)JFGVM];E@3#RVA?LMLL"M%@=!L(Q@?2KM%`%&STK3+3[/]ETVU@^RQF*W\J%5\E"02JX'R@D#@%];TCQ)H%KKF@:E;ZCIM\GF6MUW;2!XYER1E6'49!_*@!=)T31=,N)9],T>QLIKC_`%TEM;)&TG?YBH!/XTLNMBZ/)K":O)I5B^H1C:EVULAF48Q@/C@^%M)74_$>KVFEV331P">M[E$:&1VVHF3W8G`%:U`'G/[2G@2^\9_L\^)/ÒA6&PM;S5+41VJ2GR8`WFJYMR54XS@]!U-=/X5\-:?I^G:7-=Z98-JUE816SW@A5I,H@4@2$;L3$T_@M8I9X_]M9';+(=TY0\$K@9X!-8W@17D_;Z^)21OL=O">F*K?W2;?LFZ#)-\-Y]`NM_CEXB\'ZQX>U*[M=4T".:QB6TD$SMO"S1,Y5P=^XD@ECB@#WQ?C;X$/P(_X6MTUU*=%ML]7#BQO#0_&+PEX9\%_LN:;?^$/$4_B_PM_I/Q#M]=UR^$L5QO`F*W',2A"%DQD`=2:^B;?XH_#NYO-%M+3QGH]W=>(9!'MID%K=+-)MSN8XFW1M@D'J,'OGLV,!NQM[9Q4%G$/AA;>,/^$JM_`'AV+61+YHODTV(2!^N\';PV>=PYSWKM**`"O&O$M7PWO]>_:VG\2:SX>M-1\(7?@@Z3\C``N;RQCDDP.@+M$9('H:T9O!?A&7P4_@]_#&D_\(_(H1M*6SC6U*A@P'E`;?O`'IU&:WZ*`(X(MHX84AB14CC4*B@8"@#``'I4E%%`&+X=\*^&MÙ+4M1T30K#3[O6)O/U&>VMUMCDNY,D[I"!ECEF//]X^M'AGPKX:\.7>H76@:#I^F3:M:M8ZM7=^(-/N_BA^TYXD\(:OXCU[3=`\&ZM/92066CZC+9-=75SYCF>22(AFV*@55SC.3BG?L>Z?=Z3XP^*ÊWVK76KSVGBMU8VO[H*)K@"S@VM)M`!8+M!(`R1G'-`'9?$?XKV/A3Q!-HMMX/\`%_B.\M;=M+F\&A:0T\=M&V=I>1F12Q"D[%+-@=*FL/B[X#O/@P?BG'J[)X';7PWKM=]%8RWVAZE)-)I,LIPGGK(H#KG(+(7X=^$[5](TP:QXDUJZ%GHFE%RHN9MÌ=WH^HP/"?Q\\/RZ/XDB\;Z>W@SQ'X4A:74M#U*\B+O&(RZ20M2V\.:+#KGB&X@GOS9RRE([6Q@7=-0H.U5'\3-[8KI+WXEZ;HG[/=O\4_$D7V>V_L.#4KB"W^8[I8T81IG&27K:=,)K2_MTN+>5>CQNH96_$$4`7**C::)-VMZ1%\L9;+`;1ZGT%-%Q;FU^TB>,P[=WF[QMV^N>F*`)J*IZA+-M=CT?2/&UC:>8RZ=BYM86M-RJ*5#E@V8R,Y)&2:`/;J*\:^-OC_P`4^'-*^%@:/K$$FDZ/JP9M;C3$FB9FB*LS%!E`0N3P)K77;KQ=-VÌP>.M=?\8_AUJOB_]F._^&EA?V=OJ-UI$%BEU.'\D/'Y>6.`6P=AM[9Y%`'!?M)7LNH^)O@#J$_$MYXMM)I-G`W/!N/X9)KG?C)K-AXJ_:RUGPUXSM\'>*?&'AOPCI5J;/0M$LSLVAAMM2A!W)"I=MJ2+\Q4'JIX&!5SX`_ÒP+\0O@;I/C/QY;7M>M>*_%-I_:5WKS7\J7D$DI+*('5AY0C!4`*,9'3M7J_@31?B;J#:LGQ2U;PSM=:=J%G]EBTG0K&98T#9#N\TK%V+*=NT``=:\\\'_``L^//@?PRW@#P9\1O#,M?A6%W33=1O\`399=4TZ!F+;$4'RI&7H-=Y^T)H_P`'?#G@GPKX#_`SQ1\0="_:%USX._$'Q%'XG6'1XM]8TC6/L:6TSQ&01M'(B?+U)_[Y/)!`&3)XF^(/Q,_:!\9^"M'^)\/@"'PE/%M!8Z?#IL-Q=ZGNCWML^,[QH&GDOF8N9KN=0"642,I(.2YL7MXA-A!RV`HR!V)M/0&FP7W[$MU;VXTKPMI>IWUTR)%I=CHUU+=EV(&PQA?E()YR0.O-?6B@*H50M``.`.E0P6=I!,\T-K#'))]]TC"LWU('-`'SI^TM*?AE^TQX!^+]WI]P_A2STMR;0M4EM("XT]6WF-V51PO[S_`,M8,MQRM=?Y+I=+\+Z7+HO@>QT_4M4:Ô9(KRM>&X1W>.*-4*K(BHQRS8)PN.2P`/0_%7@#0_$/@^P\/:G/JCQZ7/#>+.V87!8N7P6!+$Y#,#D'%8D_P6\%G3;2WMI->L;FQOKJ]@U*TUNXCO1)MO)!*DD'%7M=^%WA+5-#UC3)8;Z!=:UE-;GN+M:ÊBGBOD$6R:*13F-E\B+`7C@\W.BZ+J*:?8WT0(""(MSN%(9(I@TT3A9%92'YY#*`#UFW^'_A2+Q8OB6/36&I+JTNK";[1(1]JDM%LWMDV[L'[*MTEE;3ZE]NO#MQ:O9FUO;^:X9(&&T1)([%T55P$`8;,#&,M5PEK^T%912:I'J_AV.!]'-A/>FPUJWOX[>TN;HVS2R/$2%>%QND3^[\RLV#CMT;P)XMM_%&J>(K>RLYDM?#^K-I?VMV!6[E2.-I2@Z@(\AC)/5D;TH`R]5^%'M@J[TKP_I\=I?6$?AFS:PTUM.U&>VD2U=8UD@:2-PSQN(XRP8DDH&SD9J[H7PMY\(Z+;O!INEM"DFA6^@$?:)&_P!!@$HBB&6_A\Z3YOO'/).!7+WOQD-OK5U.MGA*_E\*V/B%/#UWKXNHQLO&F2W)6W/SM"L\BQL^*&/21HSVUC?S6L%Q8KNV6\T!=8ALM(9;/4K5;#24T;_B7ZM3A76M^38ZS:WK2Q6[JDD4GE,?)F!DCPC9!RHP6>H:A#)'+97,LD:3,T;8#JT,JM'G@AD;8?"L5Q#I2//)(L*SH4E#!F._\L-3\!ZBGB6PUO3])DT>WOH9!*U\";M>6.6'Q8\"^&X/!=L;7Q%IUQ&_:7S?M$4JMMNC8/R-I`ZC&"17GWP)^*NO=+\6:-J$MGK7B#6].L?$4]W"RRRV]U>2)&8ME.]8Q!`ZJY[Q8(`(8Z_PA^/>@>/_`!A8:)96D,4>MV4U[I,T.J07,KQ1%,_:M88R6MG9)%=5?.1N!*L-M`'5>&?A?X-T+4K#4-/T^YÛZ;?76H07%Q?3S2&XNM8Q'/*[2.2[.HYW9P3D8JIJ/P>\$WFBV^BR0:HNDPR3M+IL6KW*6MX)IVGD6>M(/ME4RNYPP/!*_=XK.N/C"(5\1ZX_A2^'@_PO+>P7VO"ZBW-+:*WFB.WSO=/M,[email protected]^[M^:L[6OC?>>&M+UN3QCX!U+1[[2_#S^(+>R2ÂN#>6J2)&Z!U(M5)D:2,%#D?.,,W.`#J+7X3>"X/&7_"2QVE\MRNJMJ\=O_::3J?AW^SY&M)=0@>-[>]E:&&>2=24MA1'CE\TMD1A"V6I>&O'IU+7]&T>YTE;>YU;0;G6=]O?1W4"1PS0Q;4D3BM0.)U96&!@`/"UPMXLVG,RWV@KH$_\Ì$GS6*^9B+[W!_>O\P^;GKP*\_U3XYZOI%UKM46L?"_5[5?#$MJ^NRIJ-M(EK:W!`BFCVMF9P-Y>-0-H0X9LKNVO$WQ;;0OBMM9^#+S0(3_:5Y]BLIDUNV:Y>5H'E1GM03)'"WELN\\@X)4`YHÒWGP=\#7/B#MÛI;/4%8SV=S):QZK-Y)4JWW@W4_"CP!JMD-.\3>-M2:\\3QZ'+HUPL#M((!:M2FJ6:NBM/`=Q.T>9$=KA'Q(AVX-`'+Z7^SQX;M?#-UH$_B/7[JQD\-7M'AFUC*;KQ!/J%WJ,;>(MM!@T2Y,$RKY,4,LTJ21_*O7D.E6UI>MZGJ%CIS2VMC;7.?+GED!'R85B0H+``MMP"0`5#*^[=N;S8&ETZWU/3/"MU_I.IZE-J&JZ:8(+^V@2%DN8)23[3*H[.0#M3&,QLVULVIC%OC=YOD?)MQNW]LT`=QI/PK\/Z?8^'[.*ZU!XO#>N7NM6HDD0M^;-=?:O,23Y.8Q]LEP!@\+DG!R_X6_#L>!/)LM.\5:Q=:)9VYMM.TFZCMC':M19&U/-6)9I`@&U-[G"\'>,4MG\6;'2M%T&_$5AYM%OXEMIWN+>>Y-P\4B31/&0LCM$HP4,O(R02#TWQ"\#P^+/"-CHT^NZI:7>EW=M>V6J6YB^TQW,!!64JR&)B>=MRE-IW'@A-`'&^(/A+HM&L>&O%FC76H:F$\7ZE!J5[,KQ[XKB&.V2-HP4*;XLTCN(X[V98XYAARC*P$BKACF10C;'?M#MEJ\OA+Q/?"ZMFNIK>PL%DELHU17?S@7"JPW8VJS,2&VAL&@#GK3X+Z5#X=MUOPJ?%/B)O"^K6UY;PZ'YT*P6`NG9Y#$XC\TE69C&'=@F2`",8N:G\(M$UR'M4?\À*=7U;7+C6/#&^)/Q=UMZ'2_'VK^%M2MGT_2_"FAZQH4KV@/-Y+*/%M?B#Q!J&L6EM8OJ5VUO'-;VL$XG2*-8HDC&9!EV*EFXR>!C1\9>`-2FUC6=:\M):]"@^M+/!5SH-QJ6G^&1X?O;36&ECMWC#I(DT;QJS!E=&!0KAU8?,I49QO"/PTU[X5M6/\`;VBRQ^(+G1/`?]CVEDD#+)?7ZW$MQN"@X2)GD"@;LJ.IXS787GQB\"VDM,$EY>:I;(]O'=7)FT6[7^SH9'9$DO,Q_Z,K,CX,NW(4M]T$UW]`%'0#J1T.SM.LK;IJ)MD-ZMJ6,*S;1O$9;G9NSC/.,5>HHH`****`"BBB@`HHHH`****`"BMBB@`HHHH`*\>M?A9XJ)L=.N]6TY"JMRG!"9(!.*]AKSSX-_%OPQXZA2Q_M/2[/Q`T]ZKZ(NH))>#0!QOB#X5:IJ&E>+K.+6M;6,^(_&.F:_`6B%?A#XNT^3PWX:O-;T9_"7@WM6Y=8TF2*"3^T+ESYYAAFR?+58SQGTK1[`W,VEV=S;7/VAI@DIW0K,RQJT46$0("-S$DÂ_$WQ];>%/".EZYIMNGMX@_MO4K/3]/BLKJ-4N'N7"1N)6.W9R#NR>.F:2X^(>CZ!H,%[\1;C3?!MMU/YK)::AJL+,\:,H+JRG#??0D#IN&:`.9U#P)XRNOBUI'CB671-(:SCB?5[CM17N?M.JHL#JUE+$V(IH_-;H50H4DFK^N:+XZ\>_L_P6NLQ:7HOBRYDMM=1%N5=[6WD@O([F*&7#%ONQ1HY4G#%BN0`*W?'7Q'\&>%MÀU/4O$^BP#4+5MY]+$VH1QK?A4W@Q,3AE.5^89'S+ZC-+3_BIX/A\(^&=6\5>(-(\/77B;3+>^M@LKV_16'FHC$`MC*JSA=Q`&M5'(T5I+!"4D.3AF0LQV]#@!9O![>+(?%^C2:)'-Y#Z@MZAA63`].\,VGB*_\`&6AVND7ZL;2^FOXUAN`H)8(Y;#$8.0.>M#0!Q'CCX3ZWX@U?QE8C6+"'0_&OAJ#3;E_*D-U97,*2I')&,[)(SYH9E8J?DMQR&R%U;P=\6M4UC0/&-YJ/@U?$OAJ2YAM;2&&Y%C=6UQ$B3>9(29$D+QQNI5M2%"E3NW;AU]O\0-!MO#>I:]XAU+2='T_3]5FT_[2^JQ2QN4?8F64X1VX_='YME)P>:GOOB'X$L_"EGXHNO&&BQ:-J$@CM+]KZ,0W#DD;4?.&8;6R!R-ISC!H`MXWX>_"?5=!\7>'/$5]K5G//#XT\W;V8NQJ,1C:9%#L@8-@E58,^(?@BT63PCX@\.3W=]H[Z3J7]IVTWEQ*+V[N(9X=ARS*+V16MC;`8JI#+SGM?#_Q1M[WQ'H=C?6NGV=GJWA&?Q)/?IJLCRZ-IY87E^M['Y%L0`2)&)PAPRGG&0MP/>1_!"\LO!7BKPSINNP_9]8^'MAX2L)9XFW1-;0747G2A3@AOM"G:O3M:WJ*[;PF?&%U7_`(5^M)NI^(_"?BO4KSPG'JN@WURMQ9VZ7'V9K*>)$?9(WS&92A8$JJD-M.,;C9UCXMT>#O#_BJ'0/%6IZ?I=U?ZU/IE@1J,4ROY4*2^9-@CR22ZH$;+;GC_OBI?AO\M6_#?B7Q)JGAJ\U'2].URRUR^TRVTQM01KBZ2VD*^:(SA@64%MN#P"6OEO>-AE!WA5SMMP:3K4&O^*-+NK[4/!^J^'?[2:6\N)KV6[,)6[F$LA6+'D\Q1`*M-W#8"JOH?BSXS>#M*USQ7X8M=1M[OQ+X6T9]4DTPS*C7&V&27RT/)W!8@6^7MY0Z'G-:GPY^)7A#Q?X8.JV'B+1WDL["*[U6&'4(Y!IPDC\P^:P/RJ,,-QP/DM;T.`#,^(W@SQ/(/"WBOP??:4NL>&;6ZLC:ZHDGV6[@N%B#_/'EXW5H(F5@M&R-RD"-(TK2[O4ECN&6YCLMIXYU5FW%")'0,W&[CDXKÙ'P%XBET#P#?#P)K&G:5I'AVYTK4=#M-'TN[FMKM]V@#7!MYV:%TE$4J^8AWX89`61\?1?B;Q7X%-1UOP[XÒ?#'@MEO#]QI*:S-?^+/W"K?)/'*0K(H"?9Q_LUJ>%?ASXEETG0;'3M?AI/X8U'PUX/U+2]?O7>V5=>NIK18ECCDCU+0+V/PU\*[CP9)8?#;5/#][`[VL9UBM^FBA$$49BD83)&\4I$TA7F7C[SXÊYKVSAO(K2:[ACN)P3%"TBAY,==JDY./M:N7\,^/K'7OB/X@\+Z?8S-%X9V1:AJ37$(A6X:*.7RE3?YAQ'*I+E`H(9"-0M+B%[:%H8]0F:R`W(?OR,L4V9"#T.6R1MFW\!OAIR=5G8,6E?#];L[3Q+X%/ANQU:Y^SK:_:HY+UP[[93((F\^(!MF3N.5&*T]#T?Q[XXM^)%CXH?3=8^'G]B^&9-*::=+.XGGN9IX)95BCS+&84%LH\P@%B_RC`->S6=YM:7BR&TNH9Q$YCD,4@;8XZJ#_'&I?&)=:D\`+H\T,NMO0WSV&EVUO;R1303+;M]I$AENS*PAD;:QT:37!?:186M,2+'+'_9]J)/(B4A5+3)*-ORY?)[Y/EF@Z=XS&GQZT/A]XDCDT'XEW?BEK"XMAA26]L;K[5'^Y'F$/+&LZR%"5/RD`DD"OINB@#R'X/\ÀGQK*O$'C6YU"^M\+6/B+Q%_:/_``C]Q:6\LTUNEM;6Z&=_F,3N+OJ^N3\3?M$+PUH7A^]U:[DOI([+5$THPPZ?,T\]V[HB10Q[092S2*`R94\_-P7-)#(4/]MW[51U[4;3M1]%NM5U!I%M;&![B=HXGE8(BEF*H@+,`?$#X4ZW9'Q?IGP_\M*16&F:MX0T>*2UL9([6/4[B"^G:Y@+!A^]DM3Y9D;J'4%N.,GQ=\.KCQ/X=\M=ZEX6EU)+/+:^T_6OAKXP\/^!-3DTG0UNH9]&L+:&*ZT^*XMM@D8$&]4`5E5&56^7=GH#CD_`7PNU+4K[X:Q^-_`\,UEI-MXEDU.ROQ%120*ZY*2%D,F"`PXSP-OACJ'BV&/P++H5E8M$P3G2;[[0Y!?S)`L0DA\A1,I)00XR,C,'B?X7>+I[71;/Q)I.NW%E`M)T:MW_LG1[+4)]+NH8Y%N4#SL#;2%GB99H^"8QE@8TS];55OKVRLYK:*[NH8'O)OM)MUDD"F:3:S[$!^\VU';`YPI/:@#Q36?A*-?^(/Q+U'6O"MKJDNH>&;'3]ÒM]4BAF+RK;7"2%2V=C;[email protected]!QQ/C#PGKNI?"#PKX;TWX."QM5\,W5I/&MWAZRN+RWU+;&ABVO((X(Y6#R&X7)8HI)7C=]->&]7L=5[:5G56EMMY(6RCLC92158?,IY(Y&",@@UHT`?+^D?#[Q[9_%;3?%^K^&KK6=)L+'P]%?ZM3-*C-RVDK!MDGRD.[IF1$-6_@[\._$6G?&*TN/%%[email protected]_4M0DU6UT>S6UOHIC(-M$N[#6++2;9GGM8IK=KB6:^>02QL@$\?DHO*`?>$C;3P_\+=0T[5-#\00>#HHM=#EFPHM[D4`?/\`J/@CQ):0QZAK7@R[U[0;/XDZSJÎ:#$D4TE]:S+,MKM_:'XDTK5O$6MZ'932/>>'KB*"_1HF54>6%)D"L1ALI(IR.A.*VJ`/"/CWIGBMU/$7CZVT7P3JFO)XY\#QZ3IUQ920K%!:[KFI^+-*U;2/%")`8[73H7L@T8E>021F/RKC]RH^??N&=S$6V\M(^)]6_:*LM3OOA_#8P6?BJ\-Y=6VCVJ076F/:7422RW?F&6X:7?%OB*[5/!4M;%9OH::]LH]4AT^2[ACN[F.26&W:0!Y40J'95ZD*9$R1TW+GJ*S_``%XFTGQMAX5M?$6AS236%V9!$\D31L2DC1ME6&1\R-0!\Q6?PX\1V/PN\%Z;;>`[[2;?MPKK-ZGB.PM-$LKHZA*T3);WT7-&&Z3\,M1TG5]*\50>$X[;6T^*NJZG?ZFJQ_:?[*FDO@'M:3=N\EHWA_=@]U.W(S7+_L;1:;#XX$ZMKFDP6ÎZQX;O1H%W:Z?;,=1B>:*M>:>XN8YY)GEQL"O)'%D/)N&]RH^LJX72G\`^'?BJWAK0/"UM::_J%F+V_N=+MT0(D43M)L:YGC4!?,>*7:&.6*-0!XM)\.==O_"?Q.$Z1\/Y9M*U31KV2QFUM_3;6'4'U)YGF2W6=7;[3%O8R)+)@QG8-['.V/X\>%]>\4:*-/\*?"%]+LW\.M1C0A#X>LEN[>Z$\SO#+*T@%B(R(Y$\L$LTC$-N4+7T]J5W;:?I]Q?WMS';VMMK$TT\TSA8XD4%F9F/`4`$DGH!4L4B2QK)&RLC`%6!R"#T(H`^=OB-\/-9N-0M^,.G^%_!)LM6\4?9KW3M:MK:WC2_MO*LUNK/SLAA)(\-QE),(Q?HH`^=[_X-P6.H>)=2T+P/:V5]%X_T>]T"XMHHT-K9H;`W#P`$".//VPNBMA=^7R&R,Y7[.OPX\0:/XGL9O$-CXCM]=TC3K^&^N1I=G#9:E++]]Y+N-O-N@M[XD3>"P/+;2,5].T4`?)&H?`S4H/@MX8TG2_AW:IJ4OPRO[+78O+AWSZF%L9M+=)G9L/*)8YRCDD(=V&4&NUU#P[*OQ:\(^(?!7PTO[-98;&WN=/U;0[1;#3KM..>1V>*19-][email protected]:WI,S7S7/AZUM+J^2"QEG(2Y>1(MBQJS.*ZB@#P_XD^%F\M8ZY\$]4UW2=0NKJ#4#+J+Q//#]FW:7_P!7DE6&[U&UMTZ(Q1ER9KB9(8P0.@WR+D]ADT`>2?"/2K_P]^SYXF\77FD>*-:\27BZNTVGRMZG=)=7,P\2M:/=1PN+IH#O/#KE3V)K0H`\>^#NJ6_@*XUOPOJ[MZO#87/CR32/"\5V)[DF.2RAN`DIK\1=+/[0\/^#-)O/#2VEY=Q(NHI%=.[Q1HP66;P7EK*6$"QM_L?SKCNW^BFW-OY'E!/FW[,?/OKZ2;4M/&M+I#7L(OFMVN1;>8/,,08*7"]=MH9@,Î%4_`/B72_&/@O3/%.B/*^G:M;)-"VO3:U'XF2;5;U%GACDE:VBF&X>7&I";`NS(XRP8@XFL0^.9/#MO@ZS\5ZCJUKH,.A7EM#=:C:ZI.ZWZ7LD3(;]X1\QR?K/6MM2T_2--DU'5+V"SM(=OF3SR!(TW,%&6/`R2!]2*9J6JVMEJEAI\XN/.U*5X[M?R[:21`R1M(?,=5*QC:IP7(!.`,D@4`>%^!$U32?V@]%AO+_`%7QC?7EC!#?MWEQ9ZA8R:/LT]0TÛL6TEO+(F2A`D6:X/WRA"9/B*YU?5/VE+4V6A:UIDT/BMO^S]1`DU.5KO36M95,[OG[+%;.2FQ5Y#*#E7W`?05UXDT>'PO=>(HKS[9I]FMLS326,3W3$Q,R2*B1!F=E=&4JH)RI&,UJQN'C5QG##(R"#^5`'S/X8F^(-IXM=\0?V_HGB;6(_ACX>VD\1SO,UMM2%P)QJ*B".4P#SO,\M`8Q(PR*S7>W4F@:7$Z0>48M[.=!T8R"]-\GEZS::,?\`090K7-RT:Q!&90)$S,@+H2JG//ÌOHI-+2[$9^1S;AMQE'.W$A)48K_!SPIXG\,Z5\M/-5\/VFO6VLZK)K]OJL5W-M7C^(-2&NQM^";Q-;TD:9JR7,Î-$A$LTMP[1">.02JODA=XD.W**F.N\3>'?$?A[]D;28OM#;:V=0U!M*NO$\MUO$Y@%ZY"OYX.P-O2(JP4/L`:OH"B@#YKT6TU[1OMA*WC?P_K>I:Y#X9\4Q:M;Z3IFGW\2_8?*2"]M(8[IVEG4I)-.JY*B0!5QMP,M?QGIGC>UT?P=,;JXATO6K34M6UG[3%J4\-MJ=S/%+#!(MFZ2Q^5`\D4>3YM8*-QOV&OJRB@#YRO?!VM>(=?T+2/$NM^*-;L;/X9RO+J$$E[IRWM^LT7ERR(MK*PG"[F57.\')(R.*7@G1UD^)WA7Q7XOM?$EIXAUSX7VFW5(H+QF74DBD^T!MD4&-9EC6I>]$MF(_M#HRL90#*RACNR">U?3-5)+^R35HM+>[A6\N(9+B*WM+@2/'&R*[A>I56EC!/8NOJ*`/G3QYI,OB/\`9J^$&O\`Q$TW7KRXTN\TR;7WM1;L7>Y2-[1HM+AN&6!2$E1HFG21F5N$.2-G'LEO\2O#UWXET70["VUBZO=:MY+MJ-!I1W,\:27;B_C9(SO$>\!8.`/D)##:7)/L'CKQ'IOA'P9JGBG67D3M3]'LY+R[:*,NXCC4LQ51R3@'BHM#\5:1JWB[5O#=G),U]HMO:7%V'B(0)`[JQTJ*"QO[ASJ8N`YB:M-P9(YFW/L:3:,*P#!5KZ0HH`^;?#/AOQAJFH0WS#Q`VK:)\*M(FT2*YO)XK7M^VMEX"TJ%@DLP(B#"3=@-\PY!IO[,E[+X=CU3Q7KWBF]2STKPRT_B+3IM*U1M)%N8]LCW$[W;NIG4+,I6+&_?G!54Q[UI_B72[SQQJ7A2%Y3J6DV5M>7*F(A!M'.TRQD-T))@DR.V!ZUE?%;Q'X:TFST[1/$.EW.L?\)%=_9+73+>Q-TURR*96M+1]-B*A=BW&!W)`(!YYÛ)>:WJNB^"M2TN6:+PC>W3SZX\MG>N@1K8M;?:(KM9DG$7F'D9"A_+WC&:XWQU8^/K?X5>$X?!&M>)M:U^&SU.6[O+2VNK96T1G8OM`JW)+F[4&".U:0F1FCWD[2Y/U)5/5-2T_3?LXU"]AM?M=PMM;^:X7S97SM1VNX"[*)8G4JZ$J0@#P#QI9Z[XD_8J\2>(GM];O+_`,;7T>N064`>M6[M[2:\@-O#"BY*NEJD)VJ.'WGJ2:PO$0\0-H?C)_AL/%,?@J35=$%PVH0ZDM[[?,E_M-H$&*WMXX(8UCBB4*B*,!5`P`!V`%2MT`?.]O::];_L?_$-M`\07^J37$%[)H::;8WUO)8?N$`BM?M#-.X\P.ZD$@%RMJ\+@8?QS\,:CH'C"ST-4TSPN=!9M,OKH:MJ+)JLD\IGE\RVD\S[0%,#)YMN5^^$`^^\Z/5=;&B6[VJ^:HNR\D9C8C[NUXG5L_=*MD&@#YX_:"DO].7Q7)XSU+QC_'VG^*]5NO%.FF3Q/':7GQ3T:*-[2:XB==.:MWL!/Y4B$%(+4\=:5M+HJ6L=Z]@NB)BXÎJ**`"BBB@`HHHH`****`"BBMB@`HHHH`****`"BBB@`KYY^&>H:^WB+P)X5N]*\4)J'A_P`5ZV^NRW%E-+G34\,:^)M.@AU%Y?W>J0):F>")FG*MK"56,R;BI:/+9PU17"7JWFCZ-\5+?QKJ.HI\++9DL].:]FG74#QL.)(G"A45G`&AQR*=0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`453_M"W*1O`6N%MDD\L-`N\`]\D)_\À"_[M%MDG_L;QE8:G>[YECV6T7F;V&?O$;A\HY->5?&SX2>,_$/Q`\8BT\)Z?J;>*MKG3)-&\537D:R>&TMQ'O4(W[U,-,MKFVM=4C9XHKD*)%"NR?-M)'M53T/>O$G^&WQ"N_VCM*\4W/A73+*QTOQ,]V+[3A9Q))8M:-$N]PHN99MQPX7,L;$:K&TI+(7Y0C)_!7VS6_M]MS8S1:3,+H>5$A58X(VA@1MAR$PQ.6)&:ZKX4_%WPWX\6\FL8;S3X;'2M/U.:M2_$S1E3HT;J:6L'X;^)[+QIX#TCQ9IT%Q#9ZU91WD$=PH61M$=0P#`$C//8FM[&*Q>AUIIH3IVI:3M7F'C#XY>$O#/CC4O#FJ:=KRQZ+-:0:MGJT5AYEC9/M.,6]D3.I&"O)V/4!17/7GC7PE;0ZI))MXBTMCHL+3:E''=H\EHBCDR(I++ZZN8UDO6CBCD:2)-VYEQ*!T[&NT%)IK`*HEN9;=8BR.RERT61AB"'4=*-%OO@WJNM^![/5[KPQIEQIFKEKFW>73V,J/;3AG.M)%A`D*A"64M\HYKU+P_\8O#NK_$2'P=;V&IK>3ZOJ>EK*Z)Y0EL8XI)6)#YVML)E"\9)!R!7;PZQI4VGS7T6J6;6L!(EG6X4I&1U#-G`(]ZMU)[6,84:+NT]OMTL4/`.BZSHFFS6^M>+-0\1S23F1+B]MK>%HDP!Y8$,:*0""&]3OM+?3M:U*]L-4LM+^SZ?;+(]Q/=P--"(MLNH8%%.22,'UZU>\._%SPCJWA'Q#K[-?Z"2M-RC)(F3M8%3QGH1745-FGJ:1DI)-;"4ZDQ7._%#QCI/@+P/?>*M;%PUG8A-TM=M%YDTK.ZHB1ID;F9F4`9[T6;=D$I**;>QT>*,"O+]6^//@#3-.\$ZC=W-VMMGX](&F7`@'EPG]V/WYW?N\-*JD\X.U%]0\0ZUUG9:&7U2BY/WF>?_LH^#=9\&>%O$EKK'AÛT(:IXGNM2L=.M;A)MH[:WE2+8@*O:3X[N=8N`NIK;_;[=M.%HDN]E(5V*ABI&?SKZBQMW]:*U]M(YOJ5-.Z;O_PQ\Y7WPA^)6MM)M,_X1.-?#FIZ>JZ=K[236TTKP&`NT:H)%.R0LG*8"@Y/3Z%[4@JXMS:6AA.A&;=WHSY]\+^$_BIX-\2:+XST[P1HVHW5QX0M=!U;0[75$M%L9K>1VM22!RA0Q,'.4&"O'7%>A_LY^"]6\$?#V2RU^6VDU?5-4O-6U%;1F:"*:XF:0QMQE@"54$+DCD@GO7H&*.*)3;0Z=&,'HQ:***@V"BBB@`HHHH`****`"BBB@`HMHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!K#+5XSÛ)X)\1M^)O&7@C6M%\-S:]::#)?F_M+;7#I0RRR/97@#8GCM(*H7?(.XG.'#&]/TJZN--DUI;C4IHH2T=O''M7YR.%!5WQGTKV#[L?`[4YA\PH4#&!7/M*LY0C"VB_4[Z6%C3JU*J>LK?*RLCQ_\`9,T'6[*W\6>(O$.F76GWWB#799Q#M=1%'\H9*G!YQEWQ]*X?XR>#_`(@3_M`:W#X1TNX2S\8Z;!9W>J>6WD6J?*)6M+#@-MCQCJ0Q`Y(KZ8`Q[4=ZWCC9QJRJ66JM;ITM^1Q5,GI5,+##\S2B[W6[OM>_WW.>$^$],\._#VW$:8ICM+>S-N&Q\S%@=SG_`&F)+'W->*?!O6/&[email protected]\$:W\.-?UB.VNY)+/4-'@$T?3G)Y.>ZK]SDD!>O%=)=1B2WDB;CS%(/XC%2>_2@D]JQ;O*Z5CMIP:I\DG=]_^M&/FKX+WWQ"^$VGZKX&/PUU;6YFOWFL+VT(6VEW*J@O*1M5?E!SG(R00,5L_`M;P?XTA_:)\1>*O&UK(UR=/1$NEB9;6-5V9'H?6O?,UJ3>"M+5;.VETM["V_NQ*8RBD^N,@GN>:\A^$/C+QG\//!5MMX*U[X6>);ZZTMGB@N=,MQ-#.A=F!WYP.N,@G(YXZ5]"=>*3'?'TK.&(M%PFKMIN_7$P"P]6=9R(B&0EW;"-T)Q)V_NUSVAP^-?@]\6M?%=\O@K4O$VB^);O[5'=Z8OF31'?(X4J`3D>8RG..@(/:OHS'%'6M_KC6PM4\GM3=*55N#;;6BO=W:O:]OF9?A#0M-\,^&K+0])@$%G81"*%.^!U)/(],NK#4]?UF6ZDAN8RDFSCM&5/(^9G/XTSPGH.MZAÛSXA\5:EIEW#INFZ7'8Z;"*P/$1\7^-/VG/`J^+K%=+5I&OK3M11()&LX(R7WRL."[M'R!T"J*]0\3>'/C1!XLU"\\+^-]%FTR]F\R&SU2Q.;0M8`V*R#)''.'RH+.+/*1+[XZ\=3MQR2>V.(A"/.VG+ELK7OM;T/%GE]6I5]E%24.?F:=K;W>N[OV,GXSZ%KGB3]HM+X?V\.E7;Z/H\DM_=7HB)A1QAD5FZ!LQ+Q_M4GCS0=9\0?M8>%+F32KMM"T#M3Y+EKQHCY'GMN`4-TW9$9QUXKV.DX]*X8XJ225MDU]Y[4\LIS!-+\-:%IMY>?VIK$"7;01%EAA7)+N1]U=VTY/'%/\`VI/`MVL^(OAOIJ>%+=9KWP]?0WEO:9`\Y44KM7.!D9!`R,X(ZD5ZUP&Y_"CK13Q4ZM:A9?"V_6XZV6TJSJN;?OI+TMM8\>L_C!XNN;5+>T^#/BIM2V[3%/&L-N'Q_SMV;^'/?%>M6,DSVX!S4^%_NBE^@K.K4A.W+&QT8:CM5I+]Y4E_,OMO/0W7BA+G2Y`WD:;_9R(8U=110!RVH:-XQF\/V-K:^-X[6_@+_:[TZ/&XNLD[0(RVM$QQT)SBK.I:9XEF\165W9^*%M=/A5!=6)TU'-R026/FELIN&!P#C%[email protected]^(XO%D]_5I@TY%,60,?O@VYL8/;G/M5?2='\76^FZE#?>,H[MRYN$Q97`TF.+[&W/S%`Q$G5>#C[OO7344`]\5I=VMPCBRMAIB1FT8ME6+AB9-HXP0,]:Z*B@#EK/1O&,?ANZL[CQO'/J4MLBF#4/['C40*,;E\H-ALX/)/&?:EU+1O&,WAVRL[3QK':ZC`6-U??V1&XN0(O$.F76GWWB#799Q#M=1%'\H9*G!YQEWQ]*X?XR>#_`(@3_M`:W#X1TNX2S\8Z;!9W>J>6WD6J?*)6M+#@-MCQCJ0Q`Y(KZ8`Q[4=ZWCC9QJRJ66JM;ITM^1Q5,GI5,+##\S2B[W6[OM>_WW.>$^$],\._#VW$:8ICM+>S-N&Q\S%@=SG_`&F)+'W->*?!O6/&[email protected]\$:W\.-?UB.VNY)+/4-'@$T?3G)Y.>ZK]SDD!>O%=)=1B2WDB;CS%(/XC%2>_2@D]JQ;O*Z5CMIP:I\DG=]_^M&/FKX+WWQ"^$VGZKX&/PUU;6YFOWFL+VT(6VEW*J@O*1M5?E!SG(R00,5L_`M;P?XTA_:)\1>*O&UK(UR=/1$NEB9;6-5V9'H?6O?,UJ3>"M+5;.VETM["V_NQ*8RBD^N,@GN>:\A^$/C+QG\//!5MMX*U[X6>);ZZTMGB@N=,MQ-#.A=F!WYP.N,@G(YXZ5]"=>*3'?'TK.&(M%PFKMIN_7$P"P]6=9R(B&0EW;"-T)Q)V_NUSVAP^-?@]\6M?%=\O@K4O$VB^);O[5'=Z8OF31'?(X4J`3D>8RG..@(/:OHS'%'6M_KC6PM4\GM3=*55N#;;6BO=W:O:]OF9?A#0M-\,^&K+0])@$%G81"*%.^!U)/(],NK#4]?UF6ZDAN8RDFSCM&5/(^9G/XTSPGH.MZAÛSXA\5:EIEW#INFZ7'8Z;"*P/$1\7^-/VG/`J^+K%=+5I&OK3M11()&LX(R7WRL."[M'R!T"J*]0\3>'/C1!XLU"\\+^-]%FTR]F\R&SU2Q.;0M8`V*R#)''.'RH+.+/*1+[XZ\=3MQR2>V.(A"/.VG+ELK7OM;T/%GE]6I5]E%24.?F:=K;W>N[OV,GXSZ%KGB3]HM+X?V\.E7;Z/H\DM_=7HB)A1QAD5FZ!LQ+Q_M4GCS0=9\0?M8>%+F32KMM"T#M3Y+EKQHCY'GMN`4-TW9$9QUXKV.DX]*X8XJ225MDU]Y[4\LIS!-+\-:%IMY>?VIK$"7;01%EAA7)+N1]U=VTY/'%/\`VI/`MVL^(OAOIJ>%+=9KWP]?0WEO:9`\Y44KM7.!D9!`R,X(ZD5ZUP&Y_"CK13Q4ZM:A9?"V_6XZV6TJSJN;?OI+TMM8\>L_C!XNN;5+>T^#/BIM2V[3%/&L-N'Q_SMV;^'/?%>M6,DSVX!S4^%_NBE^@K.K4A.W+&QT8:CM5I+]Y40_%C_D>+C'_/./^5?*\79UB,HP$*3+XBL[RU\:_9M/A6,7-B=&WFY()W'S"@[FQ@]1SGVKS^BOS7_B).;_R0^Y_MYGTG^KN$_F?WK_([C2?$ES!I&HV]]\0/M=W=^%[[4=$U;1]._9UE^)-EJ6IZK&=3^&OB/1FN=*ML\MF4O+(H144JOSE=X&&+*5%`'W#\:/CK\//AG:Z.^MW]WJ%WXB7?I&G:-:MM>75\F`WF1QIU3!'S$@'/&>:S/#?[0/@;QE\$?%_CWPG>7('A.SN7U"SU"U:WMN+2:*)I%22-NF=O!!(SD=00/$OVD_''C>']KBZ\)ZO>^-/#OANST>)_#;>"_M#D5S?ZQ,R+OC2Y>-C$-S2IP0HV\XSD^5^&[?Q'I'_!-_XB:W+I^M7?BGXC^+MOLEPL\$LEVR[XR3+\NYBRK,2V,$R>^*`/K7_`()^ZKXS\0?LL^'_`!-X[UZ[MUK5]>[,]SMWK$962-!@`8VH&_X%4_Q0\3>(?$/[27A/X6^$=7N-/M]+C/BM/Q?=6I&X6JDI;V98@X\Z7)8598)9(Y%Z.K$-^=?3G_!3[QN=4M^)6D^!K67-OH-M]JNE!X-Q,/E!_W8P#_`-M#7S#R\*:SIEE=$"&YO+&2*-R1D`,R@9(Z`\FBW\M'>+W\(MXNA\-:L=#B/S:HMJ_D+@[2=^.@/&[H#WI.*,LPXM7\9_"O_`(5XGA#P]H6APWT=S90:7$\?MV54'"`9PV6+,SD9)8UY)13=ES6U%'%UHPY$]#T']H?XLZQ\7_$VG:UK6EVM6GS:;8"RC2T9RKJ'9]QWDG.6KH_AW^T%J.B?#>T\!>+_``3X?\;:%IK[M.AUM:,^9:]@8='7V/X$5U])S7/B/?!.N^$K@C4K?S+5FQ%>0@F)O0$_PGV/X9KGJ^R;RW@NK=K>YBCFCMD&UT=0RL/0@]17E'Q"^"ME=>9>>%9ELINIM)23"WLK=4_4?2OS?.."ZM-NI@MGS1[/=>[email protected],1H^_3YGB-M$9IUC'ORCGY?7Z5UMGHTD0W3*0U]J.P,9MG'\,1[(I[CJ?UYÔ0/B??D^&6L=0FLY+QM3=[**W*-]EM%!51E>@;C@ÔM7GM]?*YW2C2Q7)&5TDK*UK+MZGJX"3E2NUK?UOYA1117CG:%%7O#^C:KKEW]GTJMREN&SAF`PJ>[,>!^->J^"/A/96A2[\0R+?3#D6Z9$*GW[M^@]C7N95P[C\SDMO8P]WJWHE_F!_A(^.SG_?'Z(N^'8H[CQ'IUO,@>.:]A21#T96D4M$?B":^TOC')\%?!_[16@_">]^!OAZ[L]>2U4ZC;*(IH7GE>)2?%/\`9>UPM_&SQ%HG@*6PA\-Z6MO,UYK&HK%'9F9=PA9R"S$8.#@_*5R++K2_%LCW%E%J,\,ME^BR@S-),P*IM560?*.A7@G-`'U317SMI?[6FAR_&KP_X%UCX=^,?#]IXKD6M/0]7U>T6!;TNVU'$1.]8V8J`QY&Y=RKGCZ)H`****`"BBB@`HHHH`****`"BMBB@`HHHH`***CFD2&)I9&"HBEF)Z`#DF@#QO2_VE/Ù[Û)(]5M=+TNQC\RYN[J41QQ+TY)[DD`#J20M!R:_-JZ^-_B'XA>#O$GQ"\1?M$>(?!_BJ.623PSX.T:WN%LQ&@#)'(\:;&+GM*!F)/R[FR#M&WÛMXS\9_$W]D/X2^(M6\2W\>H>+KEM+N]ÀA$=MJ4T4[K]KMD`/+;XX,*%P"Y(QTH`_07X?^)=+\9>#=.\4Z(\TFF:M`MQ922PM&TD3?=?8WM(##!&0#@C@5YOÛ%^T/X7^!VH:!I^M:'K6M7OB(S?9;72(XY)0(S&,E7=2=QMD``7))!KJOV??`=Y\-?A9IW@^^\5:AXDDT\%$OKX!66/@)$B@D+&BA550>@KMY$_:TUSQ1KW_``4J\-6W@SP?)XNU'X?Z5#=1Z0EVEN)9"'F9VD?Y5V^;`?3\BÀ44`_,2:[K]H'XO?$7PY_P3;\#Z[+XBNK7QQXL^Q0IJ%LWEW+MJ0\V\$#AFBCC5B.ID/K0!]I45\C_`+=7BOX@>!/@7\+/`/ASQ7K%KXQ\2:E:M:?Q%8W:22)&8#>'//RX0O^")XU\-ZO-:/)=7EO*[@R>6PW2,D)/#MC?M4>,]!^(3W2+JNB^+X'FTZ[DY)A@0,(SD@*$&[D:!#;CO(SW`7;D$$*PMSAA6!XD^-'A?4/V'_'GB#0?!,7@[QWX=LK;PAJT;VR?;+4.8[=1YÛ9"@C5PM`V"K1XQ\H)`/1_$?[;WPKTOQ9BQOO%5EIX?3H)[email protected]#..M,Y`R0,J&&"?3OCW\\/"VBCO/%'V"XE4`;I9YY!>.WN5CCV^P51M4OP6T:_\6?M_>"O"WB!#-;_"/P!IZB"3)$=VMG`6"*[:OES_@EC>RMWGPW^(!B'_$N'C_4&L2!\NQEB8@>W3\ZÂ_B5K\7A3X=Z]XGG*^7H^F7%ZV[MH?*C9\?CMH`^>-$OCQX9_98/[0FJ?'[Q7'XH2TM]8;1O,'M]G+#,Z;(#%]S=MD4D;=N?EQ_%0!]X5XYÛ%^T/X7^!^HZ!INLZ%K>LWOB+SOMLMMI,Ò;ZU]`0_ZM?H*^?U[?6OH"'_5+]!7ZUX7?\Q/_;OZGRO$O_+KY_H24445M^N'RH4444`?+O_!1;_D(>$O^N=Y_.&OFGUKZ6_X*+?\`(0\)?]I_0>!_P!UI^B_(6BBBLSJ"BBB@`HHMHH`****`"BBB@`HHHH`KZA5[WZ6V.LHKE_\À'_%?_0_7G_@LM?_`(BCM_A'_`!7_`-#]>?\`@LM?_B*^N/+.HHKE_P#A'_%?_0_7G_@LM?\`XBC_`(1_MQ7_T/UY_X++7_P"(H`T/'W_(FZE_U[/_`"KQ.O2O%>B>(K?PY>2W7C*ZNH4AM9I(&L+=1*N.5+*@(SZCFO-:_%?$S_?Z/^']3[#AO^#/U_0****_,SZ0T_!?_M`"-VF_\`7RO\Z]O_`(17A/AV*>;7[.&VN6MII)@(YPBL8V[,%;@X]#7I_P#PMC_BO'_(_7G_@LM?_`(BOVGPQ_P!QK?XOT1\;Q)_O$/3]3J:*Y?\`X1_Q7_T/MUY_X++7_`.(H_P"$?\5_]#]>?^"RU_\`B*_33YTZBBN7_P"$?\5_]#]>?^"RMU_\`B*/^$?\`%?\`T/UY_P""RU_^(H`K_&K_`)%-?ÔE/Y&O*Z[KXDZ5K=EHM*S:CXHN-2A\Y5\F2SAC&XYPVY%!XYXZ*GJ_P`S^@,J_P"1?0_PQ_)'4T5R_P#PC_BO_H?KS_P66O\`\16YMH]O=6NGQ07M\]].@(>X>-4:3DG)50%'&!P.U/O"WP-;7?%G@K^T?$^G0.MW9Z7?Q?9[@QQEWN/.-)7MYH]B>5J/D.)/XM/T'4445Î'S04444`>-_%`8\=7MP_W/_0%KGZX[]I3XF:MX=^-&L:/;:=92QVX@VO+OW'="CK)TX5M'=Z+W7U/M9?NCZ4M(OW1]*6OV):)'GA1113`0U\^?M3_`!`T[PI\0;33[NPNMKAY-.68-$5"X,CC')Z_+7T%]*^/?V_L?\+@TW_L"Q_\`HZ6E_8F"SG_9,9%NM#ULG;5'D9WG&+RG"/%85I332UUT94_X71HG_`$!]0_[ZC_QH_P"%T:)_T!]0M_P"^H_\`&O%J*K_B$O"W_/I_^!,^+_XB=Q'_`,_%_P"`H]J7XS:(64?V/J'4M?Q1_XU]DV[9MT(_NC^5?F?']]>/XA_.OTOM3_HL?^X/Y4O\`5+*N'_\`M!_ACKO@V6TU"\TJ73]3>+4$F2QM+:T6/[5O12K;Y6B14)#?.3SM->P44`?-]MG\+OB1XJ\#^$_AQXJTNRT;3?!6DW5B^LPWZWÙ:1M.FT^"2*)0&C79.TKB3!M#*%`8$M2^)/AE\2_B9X5LM#\4Z/8>&9/#OA&_P!)M[E=16[34M0N((X4F147M,=NHB9COPY\P#:-I)^CZ*`/*?`>E^//$?Q>L_'7C7PW;^&X]$\/S:5;V*:C'M=O=7%Q+#)-,&C&%B46Z*@;YFWL2JX`/INI65>(H([M7Q!?6T0;RX;AD3>[.V`>,LQ))]R2:]U;[N!7Q!\8/B-XNT_XK>)+&UOH4AMMM4GCB4VR$A0Y`&2.>*^9XFX3QW$="%'"22E%W?,]+?Z]/^NE?GA'_K%_MWA_.OTPL_P#CUB_W%_E7S'$7_+OY_H?H_`/_`"__`.W?U,+_`(0GP_\`W-2_M\&]W_P#'*/\À"?#_P#V%I'9G;&0%^HZ*`/GG28O'WQ$U3X9:%K?PÛKPRG@?4HM6\17^HO`8);MBWM988X;1HY&,P>24OOPH"+S\QQ5KQWJ_B@_M7>'?$MM\+?&EWI'AW3-3TFXMO((+4I,]Q+:E)8@UP"T6(7))"DSM>]K7/7`P?$[XJSZ#XDM/!GAGP_)X@\6740D>QAEVQ6JD9W22$6G!)RM=N^WZ)'E8+-O:\^(JR:@FTERO772W5M^1Z*6OQ>\:>M&_&FEZ)\3O!=OI-MK4P@M;^RO!+&KD@`,,GC++GD$`YP173_`!^^)4?PWT_1M;AK:";^T]16"5IG91#``3)(-H))48P/>N7ZI6YXP2NWM9Z/YGI1S3"^RG4DVME'>Z::OMH>B8S_6@5YA\,_'GCWQ7XNCGN/`;:5X3O('EM+^YN!]H8#&PM'GYM=^00,=.YKG-(^.FM:]K>LZ#X7\'C6=6MM2FM[*&*X*1+;QG;]HGD880%N`HZM\\],M82JVTEMOJM"7FV%48MMJ[:6CN[=E8]RYHYYKPO0/C[J%K?:OX;\7^$IM8/%6GS)#9Z7ITAE-^[]%0\[]$Q1NRMC@\X4XP02#@BJ>!K*]TMK[K5>7UGV=SVM?/R\DTI]?SKSWXT_$Z#P3)-8;;8:9"VTL,XWNV#M7/YX/0`DWUO+!)J]S"M&DVR$Y^0,.ÌVXS7;B:D:E3F]I=-[:Z+Y]CQ&+>8S)IUN(O.*[?,/)9MN3C)).,M]ZQO@O\`#U/`4.ML^J-J=UKFI27T]P8!$?FZ)CS_5GGO[)(77?B-\1/&5Y\][/JQM(V;[T42LQ"CVP(MQ_P`4WXN:I:^+OVK?`_@^SD65?#\LE_>E2"$D"B15/N!&O\`W\%;&H?!'5+/MQMJVM>#/B#J/ANTUZ4RW]G!;+)EB2248D;>68@XRNXX..*TOAW\%M(\'?$L>M*]/U.>95TXVHAG0O+)*[AI+B68MEW;G^$`9K65:A[2552UY;)=G:QQPP>-=&M&&=.R4[R=UJN:]TCEM45/$/[=5I9:CAK?P[HWG6RAC^%2?%KX2Q>*_%MGXOT+Q'>>&_M$-G'Y*WML@=9$YP&7(RZ_#4V>&QD57H1I_Q&WS75DGM;YW2.O\`@?HMSX>^$OA[1KU62YM=/C6=&ZJY7++^!)'X4GQ2\'3^,].M;6+QM1K>@_9IC(SZ52\V5P%:0JNKE=MNY>NT=ZVO"NE0Z%X:T_1;9MT.GVL=O&2,$JBA1Q^%%/$^RP_+!^\WKIT2T%BM,O6)QRG65X*-EKU;UV\CS#Q9X1\/_"+X">*+GPK;RI>R6#^;?32;[B9VRJLSM\?=+D@```\XSFM3]E;3;#0/V?=#D7RHEN+4WMS*M06XB5-P`$84$\*%]>]'P-^'D?P]T74;-M4;4[K4]0>]N+IH/*)9@`%QN;I@GM.?XC5U-\+J0RNN>X('U&1WK;ZQ#MV]-[QC;_`#?XG''Ù_J>(C:U2HY/]%KZ%'P*NC^!_@OIOVB:*VT_2])22>7.M%X0,[^Y))/N37GO[&$G]I:-XP\=7*^6==UR64!^JQJ-P!ÂD8?A5K2O@5JLNMEPZ1XL^(FI:[I5A'ML-.:V$,"LJ_NVE`8F4(GYH?"^B);*PZ!YÌQ_P"1)/RKTCX-^#+?P!\/;#PM;W9N_L?FM%[@Q[#*SNSEL9./O8ZG@"L_X9_#I?"?BKQ5KSZN]]=>*+S[0Q\CRS;H"Y6-3MN.M@```]*KW*D8TK\SNDG:UEYF4O:X:K/$\KA&S;3::;Z65]R?]A^SF?X8ZEXDNM5_?^(-8N+HN>K`$+_P"A!_SJA^QZ$UKQCX_\7WN)-1NM9:V!;[\40+,%'H.5M'_`!Z5Z5\!=`D\-?!WP]HMQ&8YH+%&G1A@K(_P`[@_1F(KC-7^"6IV7C34?$M/P_\>WWA?ÛY#+?6JVJSPNY))906&.68@$'&XX('%$J].C;K_P"`CQ[]G.QMO$OQ^^(/CR>-9#::@=/L9",@`95B/?:D8SZ$^M6/M'0_X2/\`;3\+Z6!OA\.Z5)?2@?PNVX#]?*_.N\^!?P^C^''A&;1AJ;:E-=7LMEW-=/"(R[L%'W7UUA:5-QUMPVD:6\;6:6%O&@P`LA6/:!Z!2?RKA_C(K^#_`-BCM2_#ZÌ"C'5+=ZFMX'TG2_`7POL],S';V>DV&ZMXE)P,A=TDC'U)W,?K7CW[,-Y+IWPM^(/Q*GC,,>J7MW>VX88RD8=\C_@3LOUM4UMS?`G7[S3T\/:I\5M;N_"Z$`::8%65HUQMC:;/*C`ZKC@$)YS.>/E`ZU,9T::Y.:]VKOR152CB\1/VWL^7DBU%-J[;M7ET.:_8W\,V_A_X'Z9=^2%N]8#7MS(1\S;B0G/H$"X_'UK&_934:W\2/B-XTMQNCO=8^R6TG8I&6/_H)CKUW1=(32O"%MH-C,T:6=DMK#+MR5"H%5L>O`.*Y_MX%^`8OAQX%7P_%J#:@[7$EQ-,X[N[N%`LKD:1'&+,\Y)0,1)GM(X)'3WHDT;Q@?"Z62^-8UU1;C>VH_P!D1D-'S^[\G=M'4?-G/%>,?\-;:/\`M]"9J/_@7'_A1_P`-;:/_`-"9J/\`X%Q_X4?V3C?Y/Q1/^L^4?\_E]S_R/:=4MTCQ9.NF?8O&,=I]EC5;\G2HY/MK`KN89;]WD!N!G&[VJQ)IOB(^,%U%/$Z+HMX`SI7]G(2?DQGSMV[[WS=/:O#O\ÀK;1_P#H3-1_\"X_\*/^&MM'_P"A,U'_M`,"X_P#"C^R-Q=9)V@1EL)CCH3MG%6=2TSQ)-XBLKNS\4):Z?"J"ZL3IR.;D@DL?-+937M-PFVRN!I,O%O^&MM'_P"A,U'_`,"X_P#"C_AK;1_^MA,U'_P`"X_\`"C^R#/%&MPZ1J%K>:)+6-0N+OQ6MES:7"2+96O\`9B(;-BV58N&S)M'&"!GK4-CHWB^+PU=V5SXTCN-2F=3;Z@-(MC06ZC;E?*#8?.&Y)XW>U=110!R^H:/XPF\-V=G:^-([?4868W-__`&1&XN`#C[OO72T4ÌFPU"[NY&FM1)I@!M9-([?4H9&-QJ']D1N)U.["^46PF,KR#SM]ZZBBI-M3G-4TGQ3/JFGSV7BU+.VMTC6\M_[+23[6P;+,'+9CW#C`SCK4MMIOB-/&$FHM3>)DDTA@=FE_VNH_V1&`(^/W?E;MI[M_-G/-=110!R^K:-XPGTW38;'QI':75O&5O;@Z1')]L;C#!"X$?0\#/7VJU>:M;XDD\7PW\'B=(=*0+YNF?VG&/>MZB@#G]+TOQ+#KU]=7GMBE+NQG606MG_`&:D9M26RI,@;+[1QR!G.:KZ;HWC"'P[?6EWXTCNM0GV_9;XM:1'&+7&,CR@V'SSU(QFNHHH`Y:\T;QC+X:M;*V\;1P:E%(S3ZA_8\;"=3G:OME%L+C(Y!YV^]3ZEI/BF?4-.FL_%B6MO;)&+V`Z6C_;&!RS!BV8]PXP,XKHJ*M`,&'3?$:^,GU"3Q,C:0P.W2_[.0%?E`'[[=N/S9;IWQ4&D:1XLMX]2^W^,([MQKB-EL6&E1Q_8V.[#$!CYF,KPB^,1X5:Q;QM&VJ&XWKJ7]CMQ@+'Q^[\K=M/?YLYYI^JZ/XNGTO3H+'QG'9W-NF+VX.D1R?;&X^8*6`CZ'@9MZÛ=-10!@WVF^(Y?%D%_;>)T@TJ,+YNF'3D8RX!S^^+;ESD=N,>]-TW3/$L/MB*\N[SQ0EUI\PNHHH`YW5M*\4W%]ITMCXM2TAMD07L)TM)/MC`@LP8L/+W#(PM,XS4JZ;XC'C%M0;Q,K:.1@:5_9R`@[,9\[=N^]\W3VK=HH`YK2](\60?VG]MM\8QW?VE&6PQI4?VSX5_P#0?\'_`/DG1]L^%?\`T'_!_P#Y)T?ZMP3_Y\,/]2J7_`$%Q^[_@GP9O3^\OYT;T_O+^=?>?VSX5_P#0?\'_`/DG1]L^M%?\`T'_!_P#Y)T?ZP3_Y\,/]2J7_`$%Q^[_@GP9O3^\OYT;T_O+^=?>?VSX5M_P#0?\'_`/DG1]L^%?\`T'_!_P#Y)T?ZP3_Y\,/]2J7_`$%Q^[_@GP9O3^\OMYT;T_O+^=?>?VSX5_P#0?\'_`/DG0MU\+2V!KWA`YZ`"SI?ZP2_Z!Y?>'Î5M+_H+C]W_``3X,WH#PR_G7IWP#^#NO?$'7K:YN[*XLO#TN`?L'2?#WANZC6[TU-(F7^&6"R@8?@RK6X+2Z5?]!%_P#OTG^%'V6\_P"@B_\`WZ3_`Ì>TE_*_P`/\Q\J[_F6\FC)MJI]EO/\`H(O_`-^D_P`*/LMY_P!!%_\ÒTG^%'M)?RO\/\PY5W_,MY-&353[M+>?]!%_^_2?X4?9;S_H(O_WZ3_"CVDOY7^'^8?]!%_P#OTG^%'V6\_P"@B_\`WZ3_M``H]I+^5_A_F'*N_YEO)HR:J?9;S_H(O_P!^D_PH^RWG_01?_OTG^%'M)?ROM\/\`,.5=_P`RWDT9-5/LMY_T$7_[])_A1]EO/^@B_P#WZ3_"CVDOY7^'^8?]!%_P#OTG^%'V6\_P"@MB_\`WZ3_``H]I+^5_A_F'*N_YEO)HR:J?9;S_H(O_P!^D_PH^RWG_01?_OTGM^%'M)?RO\/\`,.5=_P`SF?CWHVI>(?A+K&D:3:_;+J=(C]D\P1_:XUE1Y(-QM(`\R-73DX^?GBO+O$_A/6=?O?$FKZ%X!O-$L;ZWT.3[$\-K%-J2VMY++#7N_V6\_Z"+_\`?I/\*/LMY_T$7_[])_A1[27\K_#_`#%RMKNOQ/'?^$.NKGPAJ_B/0]'\0C7;?5[36K*VU6"VM#/X_9;S_H(O\`]^D_PH^RWG_01?\`[])_A1[27\K_``_S#E7=?B>*MR?#W7%L[?3?#=IJEC`W@'5]-M+C4GA26UNKBXADBC?RCM3@-M"#"*H'48K%^M)&D2W'@+6=6LO`=QX0L=#^'^J:=?_:(HHOM,DDMK^#PG!9R+MK4V)19S-M7*E??6U_U/;'EC1E6215\PX4,MP!)]!ZTVWNK>>:2&*>.22(XD17!*_4=J^?/VC?[>\4?M*>$O"/AN]^R7=G83M3F[49-FLNY7E'^TLH;Q"8;E7DN=R!79F`>,L60*S%0P.%)%2^.M-9^%\=A+X.N=+74=VIVMHVF6EK(H$[ND:LK@*HV#;N*M\H`!P2`4K@:VJ_%?MP?8QIX(]:@B^,?@>?3H[^TGU2\MAD4'_1-*N)BK$O\`(P1#AP(I&*]0JD]*Y_4M0^%D.J76D7_A5E:UUI=,N#,@MV',#2FX=B_S0A-ZDMR",8QBM#PCKOP8BTFQMM$N[%K2X+^1A)I-C*)%(D9@3M&^'8GDUB**:9G=E?.`5.4;"MMC`+(?F'!)%.SLF+9M/+MX;>34+M()&6XFMK&22.)5@>?S"0,E"B'M#`8)(K1O?B%H%MX?TW7,W4MGJL6Û6"UEEGD)=$5%B12Q8M(HQVI9OAKX'DOMKB[;P_;B>Z8-+*CNKZU!;6')-P=,G$38*K\KE-IR[J@YY;@H])^+'ABYAMY+E=0LOM$23,LUC-FU1MT1E:/]T55M/`WA&U-DUMH-I$=/8-;;%(\L@``]>!S2U!^1A:I\9?A_86\TMYJEQ"L$4,K>99RJS>:0$105!+\\J.1@YZ&MM76OB+X9TVWLIFFNKF/4+1;N"6TLY)H_+?B,NZJ53S&PB;B-S'ÌFI?#'P'JM$T\U[X:M)GN8EB=F+9"*P8!.?DY4'*X-:%_X,\,7MUIMS=Z1!-+I$7DV3N6/MEI@`*>?F`P"-VGK7-M\'_``9)XFO-6GM;MB:*]M!;-IS38M8QE"70*`P!AI\EDOARU6&2)(BJ%UVJFW:%(;*D;%Y7!XK9TGMP_HFFJJZ?I=M;*L;Q@11A0%;;N&/0[%_(4=&/0Y*;XP^#WA\W2IKO5L7`@=+M.TD9PQE\L$#;R">\,&+""S?R\Q1(5'[M51.0LF]=VW[N>ASGH:O-X$$-H?\`8_\`8-HMF%PL2J5V\(N5(.0!)5F4^'+=1!Q'8+J5[J`MK]F$9!0+@]`0/KWIQZ7&_(P]:^+'@O2]>&BW6H30WSSRP0QRVTD:S/'@-M=EMVE=Y";AQNXS5*;XT^"87EAFN+I9;/RCJ*BV9(V,>6OELI8I6M_>:);RW-G+)+!*-RLK.'4(_,VSJ6)!=F9C@G&27?G&0&(&`@SE=8M^+-CIVO2:2VC74L\?F1L$FC_`./D3>7%!R?ORH'D7_94YYIO@3XJKXA$ZEKMTN@26T%@L+*T=P9%E$AQMW,B8=1T[8I.XR"X^(GA5-"TO64N[B>RUB-I;>:WLY90D:E0\DFU3Y:(6&MYFP!WJC_`,+7\'+&TCS:HD:Q>8)'TFX56)!98U)3F1U&Y4'++R!BM.^\`>%;MN'1[:XTWS+70PPL;9I7*)DJ?FR#NY!J%OAUX)9H,^'+/_1[AM[B/[W#N=S9YY4D`[3EÌWA00Y.#Q7H^BZIJ%K-J"6+Q?9469`1O\`,PS89`N&^4D\XQN!`F0^MX_P;\6](\0?$)/!BZ1JEGJ0MFDG\V-6C@E4MOC+H2IQM/SJ2I/`.:RKKXT)IMVBM?:OX;O+=X86G:&.2)O.C+JJ2HV_Y5)+95ANXZ>KK/XO\`P\O+IM5TS2+VM\NK8RQFX

8-k - sec€™s telephone number, including area code 011-353-1-268-2000 not applicable former name...

Documents